1. INTRODUCTION {#sec1}
===============

A common belief lasting until the early nineties was that obsessive-compulsive disorder (OCD) did not respond to placebo \[[@r1]\]. However, this view rapidly changed as reliable scales developed to measure OCD symptoms.

There are two ways to measure the response of a patient or of a group of patients to a given treatment, drug or placebo, *i.e*., to consider improvement with respect to a baseline on a predetermined rating scale in terms of points or percentage, hence providing a measure of the percent response of a group, and to define some criteria for responsiveness and provide the percentage of patients who reached or surpassed a given threshold to qualify as treatment responders. A further specification of the latter is the remitter status, based on even stricter criteria. We will call the former "placebo (or drug) effect" to differentiate it from the ambiguous term "placebo (or drug) response", and term the latter responder rate (to placebo or drug) so to hold the two concepts apart. In OCD, the most commonly used rating scale as a primary outcome measure is the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) \[[@r2], [@r3]\] and responses to treatments, or treatment effects, as we term them to avoid confusion with number of persons who are considered as treatment responders, are rated as percent variations of scores on the Y-BOCS from baseline at a given time-point. On the other hand, treatment responder rates are considered as the fraction of patients in the sample who are judged on the basis of established criteria, usually an at least 35% (or 25%, according to the study's author choice) drop of Y-BOCS scores from baseline or 1 or 2 (very much or much improved, respectively) on the Clinical Global Impressions scale, improvement version \[[@r4]\].

There is evidence for the growth of placebo effect (and responder rates) in clinical trials across the years for depression \[[@r5]\] and, less consistently, bipolar disorder \[[@r6]\], although some biases may have influenced the conclusions of this second study \[[@r7]\]. Other psychiatric disorders have not been investigated for this year-of-publication effect specifically, but a multivariate meta-analysis carried-out by Ackerman and Greenland \[[@r8]\] found an increase in the effect of placebo through the years, confirming the impressions of others \[[@r9]\]. This could be due to the host of factors, like trends in the type of patient recruited (regarding illness duration, severity, and comorbidity), type of drug used (the side effect profile of a drug like clomipramine increases the likelihood of drug identification by both clinician and patient and may affect outcome), study site characteristics (that may reflect the characteristics of participating physicians and principal investigators and contribute to large across-sites differences which are usually disregarded in most reports), outcome measures employed, publication bias-file drawer effect, and last, but not least, the fact that the more effective the drug in a study, the more effective the placebo \[[@r10]\]. In fact, a publication year effect has been shown for OCD treatment across the years \[[@r11]\]. However, Ackerman and Greenland \[[@r8]\], who used meta-regression to evaluate placebo-controlled drug trials in OCD, did not include in their remarkable paper, drug trials in paediatric populations did not consider surgical procedures *versus* sham surgery or psychotherapies *versus* sham psychological interventions, and failed to consider a considerable number of papers covering a quite long period of time. In fact, they analysed a restricted period of time of placebo-controlled drug trials of three SSRIs and clomipramine in a period spanning from 1989 to 1999 (*i.e*., after the introduction of the Yale-Brown Obsessive Compulsive Scale, Y-BOCS), with a consequent loss of more than ten years of literature.

Systematic investigations of treatment of OCD started at the dawn of the eighties, with the use of clomipramine \[[@r12], [@r13]\]; clomipramine \[[@r14]\] and imipramine \[[@r15], [@r16]\] dominated the scene during the mid-eighties, and it was only during the late eighties that SSRIs, primarily fluvoxamine, were introduced \[[@r17], [@r18]\]. The first two studies comparing sertraline to placebo appeared in 1990 and yielded contrasting results \[[@r19], [@r20]\]. The first published trials of fluoxetine *versus* placebo appeared in 1992 \[[@r21]\], but regarded data that started being gathered in the late eighties \[[@r22]-[@r24]\], therefore simultaneous with, if not preceding those of sertraline. It is noteworthy that fluoxetine had received extensive open trials in OCD since 1985 \[[@r25]\], whereas for sertraline, the two aforementioned double-blind studies were the first studies of sertraline in OCD to be published \[[@r19], [@r20]\]. This publication lag may create a bias in the attempt to clarify whether the effect of a given treatment increased or decreased with time. Unfortunately, most studies do not provide the period during which they were conducted and render it difficult to correct for this bias. Hence, we will consider publication data as a factor despite realising that it does not exactly reflect the period during which the study has been carried out.

Our aim was to extend Ackerman and Greenland's \[[@r8]\] observations beyond 2002, including also studies that did not use drugs, but other methods as well that could ensure double-blinding. We did not use the same method, but rather a JoinPoint regression.

2. METHODS {#sec2}
==========

We carried-out a general search in the PubMed-MedLine-Index Medicus and Embase-Excerpta Medica and PsycLit-Psychological Abstracts databases using the following strategy: (placebo OR sham) AND (obsessive\* OR OCD) with no time, language or any other restriction, but animal studies were subsequently excluded. We did not use the PubMed "Animal studies" function to exclude such studies, because such function often produces unreliable results. Papers were individually searched for adherence to our inclusion criteria. Retrieved relevant papers, comprising reviews and meta-analyses, were searched in their reference lists for providing additional papers with adequate research data. Final inclusion criteria for data analysis comprised: single or double-blind design, clearly stated assessment of response (responder rate or percent response on rating scales), sufficient time of treatment administration for the expected response to be observed, absence or adequate addressing of confounders that could render response not attributable to specific treatments. Specifically, the second part of cross-over studies was discarded if switching from one treatment to another had not a sufficient treatment-free wash-out period to avoid carry-over effects; survival studies were excluded when tapering-off of a combined therapy involved a drug vs. placebo when another drug or treatment was continued; add-ons were given not to patients stabilised on a given drug, but on drug-free or drug naïve populations. In this first report on placebo response in OCD we concentrate on double-blind studies using drugs, hence we excluded studies with psychotherapy or comparing mechanical devices with sham, like deep brain stimulation, electroconvulsive therapy, or deep/repetitive transcranial magnetic stimulation, provided they did not have a placebo and a drug arm. Excluded were also studies focusing on other than clinical outcomes, those carried-out on mixed populations (*e.g*., OCD and Tourette's) without providing results specific for each subpopulation, and those with designs such that a placebo effect could not be calculated.

2.1. Statistical Analysis {#sec2.1}
-------------------------

We analysed temporal trends of placebo and drug response rates/responder proportions through log-linear joinpoint segmented regression models, which identify points corresponding to statistically significant changes over time in the linear slope of the occurring trend \[[@r26]\]. We used annual mean rates of placebo and drug effect (mean placebo and drug-induced improvements and mean placebo/drug responders) as independent variable assuming constant variance (homoscedasticity) without log transformation. We applied a grid search method to fit regression functions with unknown joinpoints assuming a Poisson distribution and uncorrelated errors. We set the minimum/maximum joinpoint number from 0 to 2, and used a permutation test with overall significance level set at *p*\<0.05 and number of randomly permuted datasets of 4,499 to select the best fit. In the final model, each joinpoint indicates a trend change. We reported the estimated annual percent change (APC) for segmented analysis. Joinpoint analyses were performed using the Joinpoint Regression Program, version 3.5, from the US National Cancer Institute (<https://surveillance.cancer.gov/joinpoint/>).

3. RESULTS {#sec3}
==========

Our PubMed-MedLine-Index Medicus and Embase-Excerpta Medica, CINAHL, and PsycLit-Psychological Abstracts searches yielded 886, 2932, 164, and 994 papers, respectively, as of April 24, 2018. The total output of our research is shown in Fig. (**[1](#F1){ref-type="fig"}**), which shows also the reasons for exclusion. All studies were searched for possible further includible papers. Included were 113 studies from 112 papers,

which met criteria for inclusion. The results of the included studies \[[@r13]-[@r15], [@r17], [@r18], [@r20]-[@r24], [@r28]-[@r128]\] are summarised in Table **[1](#T1){ref-type="table"}**.

Joinpoint regression analyses of the period 1979-2017 showed that placebo mean annual effect rates in OCD studies significantly increased (APC value significantly differing from zero to α = 0.05 level) from 1991 to 2017 with an APC of 0.66% (*p*=0.04) following a period without statistically significant APC changes Fig. (**[2](#F2){ref-type="fig"}**). Placebo mean annual responder rates also significantly increased from 2010 to 2017 with an APC of 5.45% (*p*=0.02) following a period without statistically significant APC changes Fig. (**[3](#F3){ref-type="fig"}**). Drug mean annual effect rates in OCD studies significantly increased from 1987 to 2012 with an APC of 0.72% (*p*=0.04) between two periods without statistically significant APC changes Fig. (**[4](#F4){ref-type="fig"}**). Drug mean annual responder rates did not

show statistically significant APC changes between 1984 and 2017 Fig. (**[5](#F5){ref-type="fig"}**).

4. DISCUSSION {#sec4}
=============

In this study, using Joinpoint regression analyses, we found significant increases in the net effect of placebo from 1991 to 2017 and in placebo responder rates from 2010 to 2017. The effects of drug treatment of OCD increased from 1987 to 2012, between two periods of no significant changes (1979-1987 and 2012-2017), while responder rates to drug treatment showed no statistically significant annual changes between 1984 and 2017. We confirmed the finding of a trend towards an increase of placebo effects in OCD drug treatment studies, previously reported by Ackerman and Greenland for the decade 1989 to 1999 in their 2002 meta-regression \[[@r8]\]. Surprisingly, we did not find drugs to increase their effect of responder rates in parallel with placebo. In fact, the increasing placebo effect that was found for other psychiatric (*e.g*., schizophrenia \[[@r129]\] and depression \[[@r130]\]) and non-psychiatric disorders (*e.g*., hypertension \[[@r131]\]), and placebo efficacy dragged drug efficacy to higher levels \[[@r130]\]. Here we found a trend towards increased placebo effects and responder rate, with a decrease in the difference between drug and placebo, to the point that the most recent response rates (effects) between placebo and drugs nearly overlap Figs. (**[2](#F2){ref-type="fig"}**) and **4**), while responder rates differ little Figs. (**[3](#F3){ref-type="fig"}**) and **5**); something similar has been described for schizophrenia \[[@r132]\], but not for depression \[[@r130]\]. Furthermore, we also found that effect/responder rates for OCD to both placebo and drugs are low compared to other psychiatric disorders, as recently reported using effect sizes as outcome measures \[[@r133]\]. Why OCD should be stiffer than other psychiatric disorders in responding to treatment may have a response to the pathophysiology of the disorder and to its related personality characteristics. That you can't teach an old dog new tricks may well apply to this disorder. A therapeutic response may be hampered by too often controlling one's health state, that prevents a patient from establishing an adequate clinical progress, and people with OCD often display pathological doubt, that prompts them to control for any change all too often and then to doubt for results.

It is not easy to explain the increase with time of placebo effects and responder rates we found here. One explanation that has been offered for similar results in depression is the "baseline inflation" \[[@r134]\], *i.e*., the tendency to inflate baseline scores of the scale chosen for subject inclusion in a randomised clinical trial (RCT) so to ensure more participants to the sponsor. This, combined with patient expectation and the Hawthorne-like effect of being closely observed, yields better results for drug and placebo alike. However, there has been no increase in baseline Y-BOCS scores of included samples.

Other possible explanations may involve historical factors. In fact, most early studies involved testing the efficacy of clomipramine and SSRIs in patients with OCD, or were survival studies focusing on Kaplan-Meyer curves after switching patients with a benefit on an antidepressant agent to placebo, measuring recurrence/relapse rates. In contrast, later studies increasingly focused on treatment-resistant populations and add-on drugs *vs*. placebo. It is highly probable that such populations are more resistant to the effects of both drugs and placebo. However, this should have been followed by a decrease in overall responsiveness, which we did not find; on the contrary, both effect and responder rates increased in later years, more so regarding placebo Fig. (**[2](#F2){ref-type="fig"}**)-**5**).

Another issue may regard the principal sites involved in the various studies. In antipsychotic drug trials, the increase in placebo response has been observed for North America-based studies, but not for those conducted in the rest of the world or for international studies including US sites \[[@r135]\], and the same phenomenon has been observed for painkiller trials, with sample size and study duration driving the placebo response increase \[[@r136]\]. Sample size in US studies correlated weakly with placebo response in our study (Pearson's *r*=0.21). However, treatment duration did correlate strongly (Pearson's *r*=0.54). Here we observed a curious phenomenon, *i.e*., that in studies 1980-2008, US-based studies prevailed over the rest of the world (*N*=52 *vs*. *N*=24), whereas in studies conducted from 2009 on, the rest of the world studies reversed the ratio (*N*=13, USA *vs*. *N*=24, rest of the world). The reversal was driven by Iran (*N*=17), a country that was not present during the 1980-2009 period. In Iranian studies, the correlation between sample size was much weaker than in US-based studies (*r*=0.093), perhaps a consequence of the fact that sample sizes in these studies were about 20 each with a much lower standard deviation than in US studies (Table **[1](#T1){ref-type="table"}**). In contrast with US studies, there was a strong *negative* correlation between treatment duration and response to placebo (*r*=-0.471). Despite the entity of placebo effect did not differ between US-based and Iran-based studies (Student's *t*=1.145; *p*=0.256, not significant), we feel that the recent upsurge of placebo responder rates and the constant increase of placebo response are linked to the results of Iranian studies. The samples in American studies varied widely, as did the number of sites, while the Iranian studies recruited middle samples and tended to be single-center (Table **[1](#T1){ref-type="table"}**). It has been suggested in antidepressant trials for major depression that two factors that may be linked to reduced ability to detect a signal for an antidepressant are constituted by extremely large and extremely small samples and by multicentricity \[[@r137]\]; a reduced signal is usually linked to increasing placebo response that dampens the drug-placebo difference.

A possibility with longer-term treatment to associate with placebo response could reside in the exacerbating-remitting course that often characterizes OCD \[[@r138]\], especially in paediatric cases \[[@r139]\]. If the interpretation of the placebo effect as a regression to the mean holds true \[[@r140]\], it would ensure that by treating people for more time, there will be an increased probability of spontaneous remission of the disorder, that would be subsequently attributed to placebo. This matches the results of American studies, but is opposite to what Iranian studies tell us.

Still another possibility is a change in the characteristics of included patients. It has been speculated that RCTs tend to include patients repeatedly the same persons who participated in prior antidepressant trials, and this is usually addressed with excluding patients having participated recently in another RCT or having received psychotherapy in recent times. In fact, it was shown that patients with low income may be eager to participate in more than one antidepressant drug trial \[[@r141]\]. These patients would be expected to display a rather uniform behaviour in responding to treatment, thus favouring placebo response and their data tend to be increasingly included in databases, thus affecting results. In OCD, we do not have data at this regard, but the recent change in the classification of OCD spectrum disorders in the DSM-5 \[[@r142]\], which were previously classified amidst the anxiety disorders and included hoarding disorder \[[@r143]\], may have impacted the response of OCD to placebo. However, in this case, we should have expected a join point to occur about 2013, the year of introduction of DSM-5 \[[@r142]\]. In placebo effect, there was no such join point. Placebo effect showed a continuous growth from 1991 onwards, while placebo responder rate had a joinpoint at 2010, when the shift from DSM-IV-TR™ had still to occur. It should be said that DSM-IV-TR™ diagnoses in drug trials continued to be adopted along with DSM-5 diagnoses for some time. At any rate, it appears that in OCD, as in other mental and non-mental disorders, placebo effect and responder rates are puzzlingly increasing and appear to be out of control, and this depends on multiple factors \[[@r137], [@r144]\], pointing to changing populations included in RCTs (independently from initial severity) and prompting to a revision of the RCT model. Given that this trend is not specifically bound to a single condition, it is possible that it reflects continuing human evolution.

4.1. Limitations and Strengths {#sec4.1}
------------------------------

Our study is not a meta-analysis and the overall placebo effect and placebo-responder rates are not weighted for sample size. Furthermore, we did not include studies not using drugs, *i.e*., somatic treatments *vs*. sham, and did not distinguish between adult and paediatric studies. Moreover, we did not select our studies based on their quality nor did we address possible sponsor bias. However, our study is the first considering such a wide time period and the first to consider both net placebo effects and responder rates based on clear-cut criteria. Future studies will have to address the above concerns. It has been suggested that mechanical devices \[[@r145]\] and surgery \[[@r146]\] are endowed with a superior placebo effect than drugs, although the evidence is still inconclusive \[[@r147]\], and placebo, despite displaying large effects in depression, was not superior in non-pharmacological than in pharmacological studies in a meta-analysis \[[@r148]\]. Comparison between drug and somatic treatment of OCD will show whether in this disorder there is a strong mechanical device component in placebo response and whether there is an increase of response with the year of publication with these treatments similar to what occurs with drugs.

The fact that the curves of effect and responder rates did not reciprocally correspond for both placebo and drugs may be explained by the fact that some studies did not report one of them (Table **[1](#T1){ref-type="table"}**). Investigators need to report their data more clearly in the future, so to allow other investigators to perform meta-analyses on their data.

The current situation with OCD treatment is that this disorder is either treated with drugs having the ability to block the reuptake of serotonin or with cognitive-behavioral therapy or both, or with attempts to add-on ongoing pharmacotherapy other pharmacological agents having antidopaminergic or antiglutamatergic properties or somatic treatments like deep brain stimulation or transcranial magnetic stimulation. The first studies focused on the efficacy of drugs used classical designs and were carried-out by prestigious institutions. Once the concept that first line treatments were represented by SSRIs/clomipramine, the treatment paradigms shifted towards add-on and somatic treatments, and this may have affected the figures we obtained. The closing gap between placebo and drug treatment must prompt investigators to formulate new hypotheses to test and industries to produce alternatively working drugs.

CONCLUSION
==========

In this Joinpoint regression analysis, we observed an increase of the response to placebo (placebo effect) as well as an increase in responder rates in OCD studies with the year of publication. Changes in study types and sites are apparently related to the results obtained. The gap between response to drug and response to placebo appears to be reducing to an extent that current therapeutic approaches to OCD are becoming questionable and should prompt to seek newer approaches in facing this stubborn disorder.
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###### Placebo and drug responsiveness in OCD studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ---------------------------------------------------------- ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Thorén *et al*. \[[@r13]\]                                 1980       Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden                                                                                                                                                                                                  24; 8 placebo *vs*. 8 clomi *vs.* 8 nortriptyline                                                                                                                                                                                           Clomi *vs*. nortriptyline *vs*. placebo × 5 wk                                                                                                                                                                                                                                                                                                ↓ from BL of OCD Scale derived from the CPRS\                                                                                                                                                                                          7% OCD Scale                                              Not given                                                                            Clomi 50→150 mg/day\                                                                                                                                                                                                      42%;\                                                               54.54% including open clomi trial; Nortriptyline: Not given
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Responders classified according to clinicians' ratings                                                                                                                                                                                                                                                                                                                                Nortriptyline 50→150 mg/day                                                                                                                                                                                               21% OCD Scale                                                       

  Flament *et al*. \[[@r27]\]                                1985       Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD, USA                                                                                                                                                                                             19 paediatric patients; 10 received placebo first, 9 clomi                                                                                                                                                                                  11-wk Randomised Cross-over (at wk 5) Trial; Clomi *vs.* placebo                                                                                                                                                                                                                                                                              ↓O-C Rating Scale; no response criteria                                                                                                                                                                                                10.37% OCR Scale                                                                                                                               Chlomi 50→max200 mg/day                                                                                                                                                                                                   32.6% OCR Scale                                                     

  Mavissakalian *et al*. \[[@r14]\]                          1985       Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA                                                                                                                                                                                  12; 5 placebo *vs*. 7 clomi                                                                                                                                                                                                                 RCT clomi *vs*. placebo ×12 wk                                                                                                                                                                                                                                                                                                                Response: ↓Obsessive-Compulsive Neurotic Scale; Responders: Clinician Rating for OCD (5 points; score 1 on at least 3 points)                                                                                                          43% O-C Neurotic Scale                                    15.53% Clinician Rating for OCD                                                      Clomi 50→max300 mg/day                                                                                                                                                                                                    35.13% O-C Neurotic Scale                                           43% Clinician Rating for OCD

  Foa *et al*. \[[@r15]\]                                    1987       Department of Psychiatry, Medical College of Pennsylvania, Philadelphia, PA, USA                                                                                                                                                                                            37, 18 (7 scoring high \[≥21\] on the BDI) placebo *vs*.\                                                                                                                                                                                   DB RCT imipramine *vs.* placebo × 6 wk                                                                                                                                                                                                                                                                                                        Effect: ↓MOCI from BL                                                                                                                                                                                                                  3.67%\                                                                                                                                         Imipramine 25→max250 mg/day                                                                                                                                                                                               7.42% MOCI                                                          
                                                                                                                                                                                                                                                                                                                                                    19 (9 scoring high on the BDI) imipramine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        MOCI                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Perse *et al*. \[[@r17]\]                                  1987       Anxiety Disorders Center, Department of Psychiatry, University of Wisconsin, Madison, WI, USA                                                                                                                                                                               20 randomised to placebo *vs*. flexible fluvoxamine doses; 4 drop-outs for various reasons left 16 patients available for the analysis; 8 placebo first, 8 fluvoxamine first                                                                Fluvoxamine *vs*. placebo DB cross-over trial; placebo run-in × 2 wk → DB fluvoxamine *vs*. placebo × 8 wk → × 2 wk placebo → × 8 wk DB cross-over                                                                                                                                                                                            ↓from BL of Maudsley OC Inventory scores for treatment effect; Responder rate: Clinician's judgement for response                                                                                                                      -7% (Maudsley scores ↑)                                   19%                                                                                  Fluvoxamine 50 → max 150 mg/day                                                                                                                                                                                           14.54%                                                              81%

  Pato *et al*. \[[@r28]\]                                   1988       Laboratory of Clinical Science, NIMH, Bethesda, MD, USA                                                                                                                                                                                                                     21 responders to clomi ×4 months; 71.42% had significant depression; all received placebo substitution                                                                                                                                      Clomi substituted by placebo in four days, then placebo ×7 wk; survival study (relapse rates)                                                                                                                                                                                                                                                 Substitution effect: ↑Y-BOCS; ↑CPRS O-C; ↑NIMH-OC; Response: lack of relapse/recurrence; evidence of recurrence: development of "significant symptoms"                                                                                 43.7% ↑Y-BOCS; 52.78% ↑CPRS O-C; 43.87% NIMH-OC           9.52% (OCD symptoms)                                                                 Clomi tapering-off (four days, half the dosage first, than all drug substituted with placebo)                                                                                                                                                                                                 

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Goodman *et al*. \[[@r18]\]                                1989       Department of Psychiatry, Yale University School of Medicine and Connecticut Mental Health Center, Ribicoff Research Facilities, New Haven, CT, USA                                                                                                                         42; 21 placebo *vs.* 21 fluvoxamine                                                                                                                                                                                                         Multicentre (2 sites), DB RCT fluvoxamine *vs*. placebo ×6-8 wk                                                                                                                                                                                                                                                                               Effect: ↓Y-BOCS score from BL; Response: CGIi 1-2 (used different scale, but rating is similar)                                                                                                                                        0% Y-BOCS                                                 0%                                                                                   Fluvoxamine started at 50 mg/day → max 300 mg/day                                                                                                                                                                         22.4% Y-BOCS                                                        42.8%

  Jenike *et al*. \[[@r29]\]                                 1989       Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA                                                                                                                                                                                                  27: 14 placebo *vs.* 13 clomi                                                                                                                                                                                                               Multicentre\                                                                                                                                                                                                                                                                                                                                  ↓Y-BOCS scores from BL as treatment effect; no criterion for response, but stratification according to percentages of ↓Y-BOCS                                                                                                          8.46% ↓Y-BOCS                                             20-39% ↓Y-BOCS: 21.42%; ≥40% ↓Y-BOCS: 0%                                             Clomi 50→200 mg/day →max300 mg/day                                                                                                                                                                                        36.93% ↓Y-BOCS                                                      20-39% ↓Y-BOCS: 76.92%; ≥40% ↓Y-BOCS: 46.15%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (? sites), DB clomi *vs.* placebo × 10 wk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Chouinard *et al*. \[[@r20]\]                              1990       McGill University, Montréal, Québec, Canada                                                                                                                                                                                                                                 87, 44 placebo *vs.* 43 sertraline                                                                                                                                                                                                          Multicentre RCT DB sertraline, flexible doses *vs*. placebo × 10 wk                                                                                                                                                                                                                                                                           Treatment effect: % ↓Y-BOCS score from BL; % ↓NIMH-OC Scale score from BL; Response: CGIi 1-2                                                                                                                                          6.55% Y-BOCS; 6.13% NIMH-OC                               11.364% CGIi                                                                         Sertraline 50→200 mg/day                                                                                                                                                                                                  16.2% Y-BOCS; 15.2% NIMH-OC                                         25.581% CGIi

  Greist *et al*. \[[@r30]\]                                 1990       Department of Psychiatry, University of Wisconsin, Madison, WI, USA                                                                                                                                                                                                         31; 16 placebo *vs*. 15 clomi                                                                                                                                                                                                               Single site part of multicentre (21 sites) study, DB parallel RCT of clomi fixed→ flexible dose *vs*. placebo ×10 wk                                                                                                                                                                                                                          Effect: ↓NIMH-OC and ↓Y-BOCS scores from BL; Response: Patient and Physician Global Evaluation (conceptually similar to CGIi 1-2)                                                                                                      6.97% ↓Y-BOCS;\                                           5% "CGIi"                                                                            Clomi 25→200 max 300 mg/day                                                                                                                                                                                               34.883% ↓Y-BOCS 27.912% ↓NIMH-OC                                    45% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     8.64% ↓NIMH-OC                                                                                                                                                                                                                                                                                                                                                                                                                               

  Jenike *et al*. \[[@r31]\]                                 1990       Harvard Medical School, Boston, and the OCD Clinic and Research Unit, the Department of Molecular Biology, and the Inpatient Psychiatric Service, Massachusetts General Hospital, Boston, MA, USA                                                                           38; 20 placebo *vs.* 18 fluvoxamine                                                                                                                                                                                                         DB fluvoxamine *vs.* placebo × 10 wk                                                                                                                                                                                                                                                                                                          ↓Y-BOCS scores from BL as treatment effect; no criterion for response                                                                                                                                                                  4% ↓Y-BOCS                                                                                                                                     Fluvoxamine 50→max300 mg/day                                                                                                                                                                                              16.81% ↓Y-BOCS                                                      

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
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  Katz *et al*. \[[@r32]\]                                   1990       New Drug Development Department-CNS Section, Pharmaceuticals Division, CIBA-GEIGY Corporation, Summit, NJ, USA                                                                                                                                                              266 with Ham-D \<17; 129 placebo *vs*. 134 clomi                                                                                                                                                                                            Multicentre (12 sites), DB RCT clomi *vs*. placebo in pts. with DSM-III OCD and Ham-D \<17 or Ham-D 17-21 (subsequently excluded from the analysis due to small sample size) ×10 wk →responders (CGIi ≤3) with treatment confirmed (placebo, N=12, clomi, N=101) ×42 wk                                                                       Effect: ↓NIMH-OC scores from BL;\                                                                                                                                                                                                      1.96% at week 10;\                                        9.3% 10 wk; 2.4% wk 52; 16.7% at end-point (wk 70) CGIi                              Clomi 20→min 100, target 250, max 300 mg/day                                                                                                                                                                              34.69% at week 10; 55.1% at week 52; 46.94% at end-point, NIMH-OC   75.37% 10 weeks; 61.2% week 52; 72.2% at end-point (week 70) CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              response: CGIi 1-2                                                                                                                                                                                                                     21.56% at week 52; 24.71% at end-point; NIMH-OC                                                                                                                                                                                                                                                                                                                                                                                              

  Mavissakalian *et al*. \[[@r33]\]                          1990       Department of Psychiatry, Ohio State University, Columbus, OH, USA                                                                                                                                                                                                          25; 12 placebo *vs*. 13 clomi                                                                                                                                                                                                               DB RCT clomi *vs*. placebo ×10 wk                                                                                                                                                                                                                                                                                                             Effect: ↓CY-BOCS from BL;\                                                                                                                                                                                                             1.11% Y-BOCS                                              0% Much improved                                                                     Clomi 50→2-weeks 200 mg/day →flexible                                                                                                                                                                                     54.19% Y-BOCS                                                       35% Much improved
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              response: much improved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Montgomery *et al*. \[[@r34]\]                             1990       Imperial College London, St Mary\'s Hospital Medical School, London UK                                                                                                                                                                                                      14; 7 placebo first, 7 clomi first                                                                                                                                                                                                          4-wk DB clomi *vs.* placebo→cross-over ×4 wk                                                                                                                                                                                                                                                                                                  Criteria for effect or response not specified; assessment with 6-item obsessional scale extracted from CPRS and MADRS                                                                                                                  5.2%\                                                                                                                                          Clomi 75 mg/day                                                                                                                                                                                                           64.5%\                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (↓from BL of CPRS Obs Scale scores)                                                                                                                                                                                                                                                                                                                                      (↓from BL of CPRS Obs Scale scores)                                 

  McDougle *et al*. \[[@r35]\]                               1991       Connecticut Mental Health Center, New Haven, CT, USA                                                                                                                                                                                                                        30 DR (failure to reach ≥35% ↓ from BL Y-BOCS scores and CGIi\>2 and clinician consensus after fluvoxamine × 8 wk) at flexible doses up to 300 mg/day; 9 placebo *vs*. 11 add-on lithium \[study 1\]; 5 *vs*. 5 add-on lithium              DB RCT to add-on lithium *vs*. placebo ×2 wk to unchanged fluvoxamine (up to 300 mg/day) \[study 1, 20 patients\]; 4 wk blind placebo followed by 4 wk open lithium \[study 2, 10 inpatients\]                                                                                                                                                Y-BOCS (response: ↓≥35% drop from BL and Y-BOCS\<16);\                                                                                                                                                                                 Study 1:\                                                 Studies 1 & 2: 0% marked and partial (Y-BOCS, CGIi, clinician cons.)                 Clomi 200-300 mg/day + lithium 900 mg/day →0.5-1.2 mEq in plasma                                                                                                                                                          Study 1: 10.52% (Y-BOCS);\                                          Study 1: 9.091% marked, 9.091% partial (Y-BOCS, CGIi, clinician's consensus); Study 2: 0% marked and partial
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              CGIi 1-2; clinician consensus: all three=marked, 2 of 3=partial, \<2 no response)                                                                                                                                                      -5.09% (Y-BOCS scores↑)\                                                                                                                                                                                                                                                                                                                                                 Study 2:\                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Study 2: 5.83% (Y-BOCS)                                                                                                                                                                                                                                                                                                                                                  -10.66% (Y-BOCS scores↑)                                            
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  The Clomi Collaborative Study Group \[[@r36]\]             1991       Clinical Neuropharmacology, Glaxo Inc, Research Triangle Park, NC, USA                                                                                                                                                                                                      520; 120 placebo *vs*. 118 clomi (study 1)\                                                                                                                                                                                                 Multicentre (9 centres study 1; 12 centres, study 2), clomi *vs*. placebo × 10 wk; two identical studies                                                                                                                                                                                                                                      Effect: ↓CY-BOCS from BL;\                                                                                                                                                                                                             3% Y-BOCS\                                                7.5% Y-BOCS study 1\                                                                 Clomi 25→max300 mg/day                                                                                                                                                                                                    38% Y-BOCS study 1\                                                 51% Y-BOCS study 1\
                                                                                                                                                                                                                                                                                                                                                    129 placebo *vs.*\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Response ↓≥35% from BL                                                                                                                                                                                                                 study 1\                                                  7% Y-BOCS study 2                                                                                                                                                                                                                                                                                              44% Y-BOCS study 2                                                  60% Y-BOCS study 2
                                                                                                                                                                                                                                                                                                                                                    134 clomi\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       5% Y-BOCS study 2                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                    (study 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  DeVeaugh-Geiss *et al*. \[[@r37]\]                         1992       Clinical Neuropharmacology, Glaxo Inc, Research Triangle Park, NC, USA                                                                                                                                                                                                      60 children or adolescents 10-17 years, 29 placebo *vs.* 31 clomi                                                                                                                                                                           Multicentre (5 sites) DB RCT clomi *vs*. placebo × 8 wk                                                                                                                                                                                                                                                                                       Effect: ↓Y-BOCS from BL;\                                                                                                                                                                                                              8% Y-BOCS                                                 17% CGIi                                                                             Clomi 25→100, max 200 mg/day                                                                                                                                                                                              37% Y-BOCS                                                          59.8% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: CGIi 1-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Mallya *et al*. \[[@r38]\]                                 1992       McLean Hospital, Harvard Medical School, Belmont, MA, USA                                                                                                                                                                                                                   28 with HAM-D\<20; 14 placebo *vs*. 14 fluvoxamine                                                                                                                                                                                          RCT fluvoxamine *vs.* placebo ×10 wk                                                                                                                                                                                                                                                                                                          Effect: ↓Y-BOCS from BL;\                                                                                                                                                                                                              5%\                                                       7% Y-BOCS                                                                            Fluvoxamine 50→300 mg/day                                                                                                                                                                                                 33% ↓Y-BOCS                                                         43% Y-BOCS
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: ≥35%↓Y-BOCS from BL                                                                                                                                                                                                          ↓Y-BOCS                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Pigott *et al*. \[[@r39]\]                                 1992       NIH Clinical Center, Rockville Pike, Bethesda, MD, USA                                                                                                                                                                                                                      17 drug-free; 6 placebo *vs*. 11 trazodone                                                                                                                                                                                                  DB RCT trazodone *vs*. placebo ×10 wk                                                                                                                                                                                                                                                                                                         Effect: ↓Y-BOCS scores from BL                                                                                                                                                                                                         10.3% Y-BOCS                                                                                                                                   Trazodone 50→ 300 mg/day                                                                                                                                                                                                  12.98%; Y-BOCS                                                      

  Riddle *et al*. \[[@r21]\]                                 1992       Yale Child Study Center, Yale University, New Haven, CT, USA                                                                                                                                                                                                                14 (8.5-16 years); 6 placebo first *vs*. 7 fluoxetine first                                                                                                                                                                                 Cross-over randomised study fluoxetine *vs*. placebo ×20 wk (first 8 wk to one and 12 to the other in random order)                                                                                                                                                                                                                           Effect: ↓CY-BOCS scores from BL                                                                                                                                                                                                        26.72% (week 8) CY-BOCS                                                                                                                        Fluoxetine 20 mg/day                                                                                                                                                                                                      44.03% (week 8) CY-BOCS                                             

  Stein *et al*. \[[@r40]\]                                  1992       Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY, USA                                                                                                                                  35 with ≥56 on SRON and SROC; comorbidity with depression only if OCD primary and dominating; 21 placebo *vs*. 14 clomi                                                                                                                     Multicentre (2 sites) DB RCT to clomi *vs*. placebo ×10 wk                                                                                                                                                                                                                                                                                    Effect: Score ↓OCS, SRON, SROC; Response: CGIi 1-2                                                                                                                                                                                     12% OCS;\                                                 19% CGIi                                                                             clomi 25→100- 300 mg/day                                                                                                                                                                                                  29.49% OCS;\                                                        50% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     33.33% SRON;\                                                                                                                                                                                                                                                                                                                                                            40.49% SRON;\                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     31.63% SROC                                                                                                                                                                                                                                                                                                                                                              29.11% SROC                                                         

  Grady *et al*. \[[@r41]\]                                  1993       Department of Psychiatry, Duke, University Medical Center; Durham, NC, USA                                                                                                                                                                                                  13 DR (fluoxetine) OCD 80 mg/day ×10 wks; order of administration not specified                                                                                                                                                             DB cross-over to add-on buspirone *vs*. placebo ×8 wk to unchanged fluoxetine (80 mg/day)                                                                                                                                                                                                                                                     Effect: ↓Y-BOCS score from BL; Response: Y-BOCS ↓≥25% from BL and other unusual criteria                                                                                                                                               -2.9% (↑Y-BOCS scores)                                    0% (Y-BOCS)                                                                          Buspirone → 60 mg/day added on fluoxetine, 80 mg/die                                                                                                                                                                      3.91% (Y-BOCS)                                                      7.7% (Y-BOCS)
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  Hoehn-Saric *et al*. \[[@r42]\]                            1993       Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA                                                                                                                                                           21 with NIMH-OC≥9, Y-BOCS≥16; Ham-D≤21; 10 placebo *vs*. 11 clomi                                                                                                                                                                           DB CRT clomi *vs*. placebo ×10 wk                                                                                                                                                                                                                                                                                                             Effect: ↓NIMH-OC and ↓Y-BOCS scores from BL; Response: not investigated                                                                                                                                                                2.083% NIMH-OC; 5.714% Y-BOCS                                                                                                                  Clomi 25→200 mg/day; min 100 max 300 mg/day                                                                                                                                                                               31.521% NIMH-OC; 39.534% Y-BOCS                                     

  McDougle *et al*. \[[@r43]\]                               1993       Clinical Neuroscience Research Unit, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT, USA                                                                                                                                               33 DR (failure to reach ↓≥35% drop from BL Y-BOCS scores after fluvoxamine × 8 wk) at flexible doses up to 300 mg/day; 14 placebo *vs*. 19 add-on buspirone                                                                                 RCT to add-on buspirone *vs*. placebo ×8 wk to unchanged fluvoxamine (up to 300 mg/day)                                                                                                                                                                                                                                                       Y-BOCS (response: ↓≥35% from BL); CGIi 1-2; clinician consensus                                                                                                                                                                        9.09% (Y-BOCS)                                            14.29% (Y-BOCS, CGIi, clinician consensus)                                           Buspirone 15→60 mg/day added on fluvoxamine at the same dose of BL                                                                                                                                                        4.96% (Y-BOCS)                                                      10.52% (Y-BOCS, CGIi, clinician's consensus)

  Montgomery *et al*. \[[@r22]\]                             1993       Imperial College London, Paterson Wing, St Mary\'s Hospital Medical School, London UK                                                                                                                                                                                       214; 56 placebo *vs*. 52 fluoxetine, 20 mg/day *vs*. 52 fluoxetine, 40 mg/day *vs*. 54 fluoxetine, 60 mg/day                                                                                                                                Multicentre (13 sites) 8-wk DB fluoxetine 20, 40 or 60 mg *vs.* placebo                                                                                                                                                                                                                                                                       Treatment effect: ↓Y-BOCS scores Response: ≥↓25% from BL and CGIi 1-2                                                                                                                                                                  17.5% Y-BOCS                                              26%                                                                                  Fluoxetine 20,\                                                                                                                                                                                                           21.6%\                                                              36%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    40 and\                                                                                                                                                                                                                   20.5%\                                                              48%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    60 mg/day                                                                                                                                                                                                                 28.6% Y-BOCS                                                        47%

  McDougle *et al*. \[[@r44]\]                               1994       Department of Psychiatry, Yale University School of Medicine, Yale Child Study Center, New Haven, CT, USA                                                                                                                                                                   34 (failure to reach ↓≥35% drop from BL Y-BOCS scores after fluvoxamine × 7 wk) with or without tics; 17 add-on placebo *vs*. 17 add-on haloperidol                                                                                         Double-blind DR to fluvoxamine since 7 wk randomised ×4 wk to add-on haloperidol or placebo                                                                                                                                                                                                                                                   Response: Y-BOCS ↓≥35% from BL and final Y-BOCS≤16; CGIi 1-2; and consensus of clinician. Two criteria met: partial responder; all three met: marked responder                                                                         7.63%                                                     0%                                                                                   Fluvoxamine up to 300 mg/day; dose unaltered during trial; add-on haloperidol 2→max10 mg/die (mean, 6.2 mg)                                                                                                               27.17%                                                              65%

  Tollefson *et al*. \[[@r23]\]                              1994       Psychopharmacology Division, Eli Lilly & Co., Indianapolis, Ind, USA                                                                                                                                                                                                        355; 89 placebo *vs*. 87 fluoxetine 20 mg, *vs*. 89 fluoxetine 40 mg *vs*. 90 fluoxetine 60 mg                                                                                                                                              Multicentre (8 sites), DB fluoxetine at fixed doses *vs*. placebo × 13 wk                                                                                                                                                                                                                                                                     Y-BOCS ↓ from initial score for effect;\                                                                                                                                                                                               -1.2%\                                                    8.5%                                                                                 Fluoxetine 20 mg/day\                                                                                                                                                                                                     15.24%\                                                             32.1%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Y-BOCS ↓≥35% for response                                                                                                                                                                                                              (mean Y-BOCS scores ↑)                                                                                                                         40 mg/day\                                                                                                                                                                                                                20.26%\                                                             32.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    60 mg day                                                                                                                                                                                                                 25.99%                                                              35.1%

  Tollefson *et al*.\* \[[@r24]\]                            1994       Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, Indiana, USA                                                                                                                                                                       76 responders of the previous study with their treatment confirmed; 6 placebo *vs*. 23 fluoxetine 20 mg, *vs*. 21 fluoxetine 40 mg *vs*. 26 fluoxetine 60 mg                                                                                Multicentre (8 sites), DB fluoxetine at fixed doses *vs*. placebo × 6 months (extension)                                                                                                                                                                                                                                                      Y-BOCS ↓ from initial score for effect;\                                                                                                                                                                                               -6.25%\                                                   50% Y-BOCS                                                                           Fluoxetine 20 mg/day\                                                                                                                                                                                                     10.09%\                                                             47% Y-BOCS
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Y-BOCS ↓≥35% for response                                                                                                                                                                                                              (mean Y-BOCS scores ↑), but at BL patients were not OCD                                                                                        40 mg/day\                                                                                                                                                                                                                11.32%\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    60 mg day                                                                                                                                                                                                                 23.91% Y-BOCS, but at BL patients were not OCD                      
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  Greist *et al*. \[[@r45]\]                                 1995       Dean Foundation for Health, Research, and Education, Madison, Wisconsin, USA                                                                                                                                                                                                325; 84 placebo *vs*. 241 sertraline: 80 sertraline 50 mg/day; 81 sertraline 100 mg/day; 80 sertraline 200 mg/day                                                                                                                           Multicentre (11 sites), DB parallel comparison of three dosages of sertraline *vs*. placebo ×12 wk                                                                                                                                                                                                                                            Effect: ↓Y-BOCS score from BL;\                                                                                                                                                                                                        14.6%\                                                    30%\                                                                                 Sertraline, pooled\                                                                                                                                                                                                       23.4%\                                                              38.9% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥25% from BL CGIi 1-2                                                                                                                                                                                                ↓Y-BOCS                                                   CGIi                                                                                 50,\                                                                                                                                                                                                                      27.37%\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    100, and\                                                                                                                                                                                                                 22.83%\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    200 mg/day                                                                                                                                                                                                                33.02% ↓Y-BOCS                                                      

  Fux *et al*. \[[@r46]\]                                    1996       Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gunion University of the Negev, Beersheva, Israel                                                                                                                                                  13 partial or complete non-responders to clomi/SSRIs or with severe side effects; 6 placebo first, 7 inositol first                                                                                                                         Cross-over RCT inositol *vs.* placebo ×6 wk; cross-over ×6 wk without washout                                                                                                                                                                                                                                                                 Response criteria not specifically stated, but data given so that we extrapolated % ↓Y-BOCS scores for response and calculated % of patients who achieved ↓Y-BOCS≥35% (or 25%) from BL for response                                    1.55% Y-BOCS; Placebo first at 6 wk: 12.4%                0% ↓Y-BOCS≥ 35%\                                                                     Oral inositol 18 g/day                                                                                                                                                                                                    21.104% Y-BOCS; Inositol first at 6 wk: 25.01%                      30.77% ↓Y-BOCS≥ 35%; Inositol first at 6 wk: 28.57%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Placebo first at 6 wk: 0% ↓Y-BOCS≥ 25%                                                                                                                                                                                                                                                                                                                                             (57.14% ↓Y-BOCS≥ 25%)

  Goodman *et al*. \[[@r47]\]                                1996       Department of Psychiatry, University of Florida College of Medicine, Gainsville, FL, USA                                                                                                                                                                                    156; 78 placebo *vs.* 78 fluvoxamine                                                                                                                                                                                                        Multicentre (4 sites), DB RCT fluvoxamine *vs*. placebo ×10 wk                                                                                                                                                                                                                                                                                Effect: ↓Y-BOCS score from BL; ↓NIMH-OC score from BL;\                                                                                                                                                                                5.42% Y-BOCS;\                                            8.6%                                                                                 Fluvoxamine started at 50 mg/day → max 300 mg/day                                                                                                                                                                         21.14% Y-BOCS;\                                                     43.4%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: CGIi 1-2                                                                                                                                                                                                                     3.89% NIMH-OC                                                                                                                                                                                                                                                                                                                                                            19.101% NIMH-OC                                                     

  Nakajima *et al*. \[[@r48]\]                               1996       Department of Neuropsychiatry, Kyoto Perfectural University of Medicine, Kawaramachi-Hirokoji, Kamigyoku, Kyoto, Japan                                                                                                                                                      27 fluvoxamine 300 mg/die *vs*. 34 fluvoxamine 150 mg/die *vs*. 33 placebo                                                                                                                                                                  DSM-III-R OCD patients assigned to one of three groups: high-dose fluvoxamine *vs*. low-dose fluvoxamine *vs*. placebo × 8 wk                                                                                                                                                                                                                 Y-BOCS scores (%↓Y-BOCS from BL; response ↓≥35% from BL)                                                                                                                                                                               7.25%                                                     36.36%                                                                               Fluvoxamine 150 mg/day\                                                                                                                                                                                                   28.33%;\                                                            79%;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    300 mg/day                                                                                                                                                                                                                29.96%                                                              77.8%

  Zohar *et al*. \[[@r49]\]                                  1996       Chaim Sheba Medical Centre, Tel-Hashomer, Israel, and Sackler Medical School, Tel Aviv University, Israel                                                                                                                                                                   399; 99 placebo *vs*. 201 paroxetine *vs*. 99 clomi                                                                                                                                                                                         Multicentre-multinational (? sites), DB paroxetine *vs*. clomi *vs*. placebo × 12 wk                                                                                                                                                                                                                                                          Y-BOCS ↓≥25%                                                                                                                                                                                                                           18.87%                                                    35.4%                                                                                Paroxetine 20-60 mg/day; Clomi 50-250 mg/day                                                                                                                                                                              30.77%;\                                                            55.1%;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              32%                                                                 55.3%

  Jenike *et al*. \[[@r50]\]                                 1997       Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA                                                                                                                                                                           64; 21 placebo *vs.* 20 phenelzine *vs.* 23 fluoxetine                                                                                                                                                                                      10-wk fluoxetine *vs*. phenelzine *vs.* placebo                                                                                                                                                                                                                                                                                               ↓Y-BOCS scores from BL as treatment effect                                                                                                                                                                                             1%                                                                                                                                             Phenelzine 60 mg/day,\                                                                                                                                                                                                    9.4%;\                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Fluoxetine 80 mg/day                                                                                                                                                                                                      14.7%                                                               
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  Lindsay *et al*. \[[@r51]\]                                1997       Clinical Research Unit for Anxiety Disorders, School of Psychiatry, University of New South Wales at St Vincent's Hospital, Sydney, NSW, Australia                                                                                                                          18 (13 drug-free, 5 unresponsive to clomi or fluoxetine); 9 placebo (anxiety management) *vs*. 9 CBT                                                                                                                                        Parallel assignment to CBT (ERP) *vs*. anxiety management assumed as the placebo (5 1-h sessions per wk × 3 wk); control group also did homework                                                                                                                                                                                              Treatment effect: ↓Y-BOCS from BL; ↓MOCI from BL; ↓PADUA scores from BL; Response criteria: not provided                                                                                                                               -5.93% (↑Y-BOCS); 12.002% MOCI; 15.201% PADUA                                                                                                  CBT in 15 sessions divided in three weeks, about 1 hour per session, for both ERP and anxiety management (hyperventilation and respiration and relaxation control with no cognitive restructuring and exercise at home)   61.67% Y-BOCS;\                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              43.76% MOCI;\                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              50.99% PADUA                                                        

  Ushijima *et al*. \[[@r52]\]                               1997       Department of Psychiatry, Jikei University School of Medicine, Nishishinbashi, Minato-ku, Tokyo, Japan                                                                                                                                                                      33 150 mg/die fluvoxamine *vs*. 29 300 mg/die fluvoxamine *vs*. 42 placebo                                                                                                                                                                  Multicentre, DB fluoxetine at fixed doses *vs*. placebo × 8 wk                                                                                                                                                                                                                                                                                Y-BOCS ↓ from initial score for effect;\                                                                                                                                                                                               11.66% (mean Y-BOCS ↓)                                    38.1% Y-BOCS                                                                         Fluvoxamine 150 mg/day\                                                                                                                                                                                                   23.9%\                                                              55.17%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Y-BOCS ↓≥35% for response                                                                                                                                                                                                                                                                                                                                                             300 mg/day                                                                                                                                                                                                                24.05% (mean Y-BOCS ↓)                                              51.51% Y-BOCS

  Fallon *et al*. \[[@r53]\]                                 1998       Department of Psychiatry, Columbia University, Division of the New York State Psychiatric Institute, New York, NY, USA                                                                                                                                                      54, 29 DR placebo *vs*. 25 DR i.v. clomi                                                                                                                                                                                                    DR to oral clomi, randomised to i.v. clomi *vs*. placebo × 14 days                                                                                                                                                                                                                                                                            Effect: %↓Y-BOCS from BL; %↓CGIs from BL; %↓NIMH-OC from BL;\                                                                                                                                                                          3.3% Y-BOCS; 0% CGIs; 0% NIMH-OC                          0% CGI; 0% Y-BOCS                                                                    Intravenous (i.v.) Clomi 250 mg/day                                                                                                                                                                                       11.8%\                                                              20.7%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              response ↓≥25% from BL; CGIi 1-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Y-BOCS; 10.1% CGIs; 9.565% NIMH-OC                                  CGIi\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  21.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Y-BOCS

  Li, J. *et al*. \[[@r54]\]                                 1998       Mental Health Center of Sichuan province, Mianyang, China                                                                                                                                                                                                                   42; 12 placebo *vs.* 15 clomi *vs.* 15 paroxetine                                                                                                                                                                                           DB CCMD-2 OCD paroxetine 20→80 mg/day *vs*. 50→300 mg/day *vs*. placebo ×4 wk                                                                                                                                                                                                                                                                 Effect: ↓Y-BOCS from BL; unclear response criteria                                                                                                                                                                                     10.06%                                                                                                                                         20-80 mg/day paroxetine,\                                                                                                                                                                                                 51.32%\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    50-300 mg/day clomi                                                                                                                                                                                                       48.71%                                                              

  March *et al*. \[[@r55]\]                                  1998       Departments of Psychiatry and Psychology, Duke University Medical Center, Durham, NC, USA                                                                                                                                                                                   189 children and adolescents; 95 placebo *vs*. 92 sertraline                                                                                                                                                                                Multicentre (12 sites), RCT Sertraline flexible doses *vs.* placebo ×12 wk                                                                                                                                                                                                                                                                    Effect: ↓CY-BOCS from BL;\                                                                                                                                                                                                             15.31% ↓CY-BOCS                                           37% ≥25%↓CY-BOCS                                                                     Sertraline 25-50→max200 mg/day                                                                                                                                                                                            29.05%\                                                             53% ≥25%↓CY-BOCS
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: ≥25%↓CY-BOCS from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ↓CY-BOCS                                                            

  Kronig *et al*. \[[@r56]\]                                 1999       Department of Psychiatry, Hillside Hospital of LIJMC, Glen Oaks, New York, NY, USA                                                                                                                                                                                          167; 81 placebo *vs*. 86 sertraline                                                                                                                                                                                                         Multicentre (10 sites), Double-blind sertraline 50-200 mg/die randomised *vs*. PLC ×12 wk                                                                                                                                                                                                                                                     CGIi 1-2 (response), ↓Y-BOCS from BL; ↓NIMH from BL (primary outcome)                                                                                                                                                                  17.16% Y-BOCS                                             23.45% CGIi                                                                          Sertraline 50-200 mg/day                                                                                                                                                                                                  38.08%                                                              41.8%

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Dannon *et al*. \[[@r57]\]                                 2000       Psychiatry Department, Chaim Sheba Medical Center, Tel Hashomer, Israel                                                                                                                                                                                                     14 DR to 60 mg/day paroxetine ×≥15 wks\                                                                                                                                                                                                     DB RCT of DR, ×6 wk to add-on pindolol or placebo                                                                                                                                                                                                                                                                                             Unresponsiveness: Y-BOCS ↓\<25% from BL;\                                                                                                                                                                                              7.69%                                                                                                                                          Paroxetine 60 mg/day; add-on pindolol 7.5 mg/die                                                                                                                                                                          25.69%                                                              
                                                                                                                                                                                                                                                                                                                                                    (Y-BOCS ↓\<25%),\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Effect of treatment:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                    6 placebo *vs*.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ↓Y-BOCS scores from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                    8 pindolol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  McDougle *et al*. \[[@r58]\]                               2000       Department of Psychiatry, Section of Child and Adolescent Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA                                                                                                                                          36 SSRI-refractory; 16 placebo *vs*. 20 add-on risperidone                                                                                                                                                                                  Double-blind refractory to clomi, fluvoxamine, sertraline, fluoxetine, and paroxetine (failure to reach ↓≥35% drop from BL Y-BOCS scores), randomised ×6 wk to add-on risperidone or placebo                                                                                                                                                  Response: Y-BOCS ↓≥35% from BL and final Y-BOCS≤16; CGIi 1-2; and consensus of clinician. Two criteria met: partial responder; all three met: marked responder                                                                         9.42%                                                     0                                                                                    Clomi, fluvoxamine, sertraline, fluoxetine, or paroxetine at fixed dose; add-on risperidone 1-6 mg/die (mean, 2.2 mg)                                                                                                     31.8%                                                               50%

  Geller *et al*. \[[@r59]\]                                 2001       Pediatric OCD Clinic, McLean Hospital, Belmont,\                                                                                                                                                                                                                            103 with ≥4 on the CGIs and ≥16 on the CY-BOCS (7-18 years); 32 placebo *vs*. 71 fluoxetine                                                                                                                                                 Multicentre (21 sites), 13-wk, DB RCT 2:1. Fluoxetine *vs.* placebo                                                                                                                                                                                                                                                                           CY-BOCS scores (response ↓≥40% from BL)                                                                                                                                                                                                19.7%                                                     25%                                                                                  Fluoxetine, mean 24.6 mg/day                                                                                                                                                                                              38.7%                                                               49%
                                                                        MA, USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Montgomery *et al*. \[[@r60]\]                             2001       Imperial College of Science, Technology and Medicine, London, UK                                                                                                                                                                                                            401; 101 placebo *vs.* 102 20 mg citalopram, *vs*. 98 40 mg citalopram, *vs*. 100 60 mg citalopram                                                                                                                                          Multicentre (53 sites), multinational (12 countries); randomisation to citalopram *vs*. placebo ×12 wk                                                                                                                                                                                                                                        Treatment effect: ↓Y-BOCS scores Response: ≥↓25% from BL                                                                                                                                                                               22.05%                                                    36.6%                                                                                Citalopram 20 mg/day\                                                                                                                                                                                                     33.47%\                                                             57.4%;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    40 mg/day or\                                                                                                                                                                                                             34.23%\                                                             52%;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    60 mg/day                                                                                                                                                                                                                 40.15%                                                              65%;

  Riddle *et al*. \[[@r61]\]                                 2001       Division of Child and Adolescent Psychiatry, Johns Hopkins Hospital, Baltimore, MD, USA                                                                                                                                                                                     120 (8-17 years); 63 placebo *vs*. 57 fluvoxamine                                                                                                                                                                                           Multicentre (17 sites) DB RCT fluoxetine *vs*. placebo × 10 wk                                                                                                                                                                                                                                                                                Effect: ↓CY-BOCS scores from BL; Response: CY-BOCS ↓≥25% from BL                                                                                                                                                                       13.63% CY-BOCS                                            26%                                                                                  Fluvoxamine 25→ 50-max 200 mg/day                                                                                                                                                                                         24.79% CY-BOCS                                                      42.1%

  Romano *et al*. \[[@r62]\]                                 2001       Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA                                                                                                                                                                                                  71 responders (out of 130) to 20-wk 20, 40 or 60 mg fluoxetine with ↓≥25% drop from BL; 35 placebo *vs*. 36 fluoxetine                                                                                                                      Multicentre\                                                                                                                                                                                                                                                                                                                                  No relapse                                                                                                                                                                                                                             62%                                                                                                                                            Fluoxetine 20, 40 or 60 mg/day                                                                                                                                                                                            82.5%; only 60 mg/die fluoxetine different from placebo             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (11 sites), randomisation to fluoxetine as before *vs*. placebo × 52 wk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Atmaca *et al*. \[[@r63]\]                                 2002       Fırat Üniversitesi Hastanesi, Fırat Tıp Merkezi, Psikiyatri Anabilim Dalı, Elazig, Turkey                                                                                                                                                                                   27 DR (one 3-month trial of 25→300 mg/day clomi or 50→300 mg/day fluvoxamine or 20→80 mg/day fluoxetine yielded CGIi ≥3 and Y-BOCS ≥18 and clinician consensus) to SSRIs or clomi ×2 months), 13 placebo *vs*. 14 DR to quetiapine add-on   Single-blind randomisation of DR patients with stabilised SSRI or clomi to add-on quetiapine or placebo × 8 wk                                                                                                                                                                                                                                Treatment effect: ↓Y-BOCS score from BL; ↓CGIs from BL; response: significant improvement, ≥60% ↓Y-BOCS score from BL; partial improvement, ≥30-59% ↓Y-BOCS score from BL plus clinician consensus                                     10.08% (↓Y-BOCS);\                                        0%                                                                                   Stable SSRI or clomi;\                                                                                                                                                                                                    44.4% (↓Y-BOCS);\                                                   71.4%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     15.88% (↓CGIs)                                                                                                                                 add-on quetiapine flexible, *i.e*., 50 mg/day → ↑25 mg/day when Y-BOCS did not ↓ by 2 from previous evaluation                                                                                                            47.161% (↓CGIs)                                                     

  Greist *et al*. \[[@r64]\]                                 2002       Healthcare Technology Systems, University of Wisconsin, Madison, WI, USA                                                                                                                                                                                                    218 (age 15-80), Y-BOCS≥16, not comorbid with psychoses and Tourette's; 75 placebo (relaxation) *vs*.74 computer-guided *vs*. 69 therapist-guided                                                                                           Multicentre (8 sites), parallel comparison of three psychotherapies, computer-assisted CBT, therapist-conducted CBT *vs*. relaxation assumed as the placebo × 10 wk (therapists not raters)                                                                                                                                                   Effect: ↓Self-rated Y-BOCS score from BL; Response: Y-BOCS ↓≥25% from BL CGIi 1-2; PGIi 1-2                                                                                                                                            6.6% ↓Self-rated Y-BOCS\                                  15% PGIi; 14% CGIi                                                                   Computer-guided CBT, 9 steps: 1-3 education and assessment; 4-9 self ERP ×1 h or more;\                                                                                                                                   22.77%\                                                             38% PGIi;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \                                                                                                                                              Clinician-guided CBT, one 1-hour weekly session ×11 weeks ERP + homework                                                                                                                                                  \                                                                   38% CGIi\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Relaxation, 1-h/day ×10 weeks                                                                                                                                                                                                                                                                                                                                            \                                                                   \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              30.16% ↓Self-rated Y-BOCS                                           58% PGIi 60% CGIi

  Koran *et al*. \[[@r65]\]                                  2002       Department of Psychiatry, Stanford, CA, USA                                                                                                                                                                                                                                 223 responders to 16 or 52-wk 50-200 mg/day sertraline with Y-BOCS ↓≥25% from BL *and* CGIi ≤3; 114 placebo *vs.* 109 sertraline                                                                                                            Multicentre (21 sites), DB randomisation to flexible sertraline or to placebo × 28 wk                                                                                                                                                                                                                                                         No relapse, defined as either ↑Y-BOCS scores ≥5 from randomisation and total score of ≥20 and ↑CGIi score of ≥1; Insufficient clinical response                                                                                        76%                                                                                                                                            Sertraline flexible doses 50-200 mg/day                                                                                                                                                                                   91%                                                                 

  Liebowitz *et al*. \[[@r66]\]                              2002       New York State Psychiatric Institute and Department of Psychiatry\                                                                                                                                                                                                          43 (children 6-18 years); 22 placebo *vs*. 21 fluoxetine (acute); 7 placebo *vs.* 11 fluoxetine (extension)                                                                                                                                 Multicentre (2 sites), RCT fluoxetine *vs*. placebo ×8 wk (acute phase) → responders extension ×8 wk                                                                                                                                                                                                                                          CGIi 1 or 2 (response), ↓CY-BOCS from BL (primary outcome)                                                                                                                                                                             22.12% acute;\                                            31.81% (CGIi)                                                                        Fluoxetine 60-80 mg/die                                                                                                                                                                                                   34.62% acute; 74.36% extension                                      57.14% CGIi
                                                                        at Columbia University, New York, NY, USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    54.6% extension                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Geller *et al*. \[[@r67]\]                                 2003       Obsessive Compulsive Disorder Program and Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA                                                                                                            8-17 yr-old children who responded to 16-wk 10-60 mg/day paroxetine; 98 placebo *vs*. 95 paroxetine                                                                                                                                         Multicentre\                                                                                                                                                                                                                                                                                                                                  CY-BOCS (response ↓≥25% from BL and CGIi 1 or 2);\                                                                                                                                                                                                                                               56.1%                                                                                Paroxetine flexible doses (10-60 mg/die)                                                                                                                                                                                  65.3%                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (? sites); paroxetine-responder children aged 8-17 randomised to paroxetine as before *vs*. placebo ×16 wk                                                                                                                                                                                                                                    No relapse; relapse defined as ↑CGI by 1 in two follow-up visits or ↑CGI by 2 at any time or CGI≥5 at any time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Hollander *et al*. \[[@r68]\]                              2003       Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                             27, 10 placebo *vs*. 17 clonz                                                                                                                                                                                                               Multicentre\                                                                                                                                                                                                                                                                                                                                  CGIi 1-2                                                                                                                                                                                                                               2.6%Y-BOCS                                                22% CGIi                                                                             Clonz 3-6 mg/day                                                                                                                                                                                                          7% Y-BOCS                                                           6.2% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (2 sites), DR + drug- naïve patients randomised 2:1 to clonz or placebo × 10 wk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Hollander *et al*. \[[@r69]\]                              2003       Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                             16 DR (CGIi≥3 after at least two trials of SSRIs, clomi or venlafaxine for 12 wks), 6 placebo *vs*. 10 add-on risperidone                                                                                                                   DB RCT of DR patients to risperidone *vs*. placebo × 8 wk added on stable previous SSRI, venlafaxine or clomi                                                                                                                                                                                                                                 Effect: ↓Y-BOCS score from BL\                                                                                                                                                                                                         4.53% Y-BOCS                                              0% Y-BOCS and CGIi                                                                   Risperidone 0.5→max 3 mg/day add-on to minimum mg/day: 200 clomi, 60 fluoxetine, 150 fluvoxamine, 150 sertraline, 60 citalopram or 325 venlafaxine                                                                        20.89% Y-BOCS                                                       40% Y-BOCS *and* CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥25% and CGIs ↓≥2 points from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Hollander *et al*. \[[@r70]\]                              2003       Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                             89 placebo *vs.* 88 paroxetine, 20 mg/day, *vs.* 86 paroxetine, 40 mg/day, *vs.* 85 paroxetine, 60 mg/day                                                                                                                                   Multicentre (15 sites), paroxetine, three fixed doses with an about 1:1:1:1 randomisation DB *vs.* placebo × 12 wk                                                                                                                                                                                                                            Effect: ↓Y-BOCS score from BL\                                                                                                                                                                                                         13% Y-BOCS                                                Not provided                                                                         Paroxetine 20,\                                                                                                                                                                                                           16%\                                                                Not provided
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥25% and CGIs ↓≥2 points from BL                                                                                                                                                                                                                                                                                                                                    40,\                                                                                                                                                                                                                      25%\                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    60 mg/day                                                                                                                                                                                                                 29% Y-BOCS                                                          

  Hollander *et al*. \[[@r70]\]                              2003       Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                             105 responders to paroxetine randomised to placebo (*N*=52) or to paroxetine (*N*=53) 20-60 mg/day                                                                                                                                          Multicentre (15 sites), Paroxetine responders to flexible paroxetine doses (20-60 mg/day) or placebo × 6 months                                                                                                                                                                                                                               Non-relapse: relapse defined as return of Y-BOCS to BL values or ≥1↑CGI at any time-point                                                                                                                                                                                                        41.2% Y-BOCS/ CGIi                                                                   Paroxetine 20, 40 or 60 mg/day                                                                                                                                                                                                                                                                62.3% Y-BOCS/ CGIi

  Hollander *et al*. \[[@r71]\]                              2003       Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                             253; 126 placebo *vs.* 127 fluvoxamine controlled-release                                                                                                                                                                                   Multicentre\                                                                                                                                                                                                                                                                                                                                  Effect: ↓Y-BOCS score from BL\                                                                                                                                                                                                         19.01% Y-BOCS                                             23% CGIi                                                                             Fluvoxamine 100 → 100-300 mg/day                                                                                                                                                                                          34.56% Y-BOCS                                                       44% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (5? sites) RCT Fluvoxamine controlled-release 100-300. placebo × 12 wk                                                                                                                                                                                                                                                                        Response: CGIi 1 or 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Bystritsky *et al*. \[[@r72]\]                             2004       Department of Psychiatry and Biobehavioral Sciences, Anxiety Disorders Program, University of California at Los Angeles (UCLA) School of Medicine, Los Angeles, CA, USA                                                                                                     26 DR (unchanged after two adequate antidepressant trials and a course of behavioural psychotherapy), 13 placebo *vs*. 13 risperidone                                                                                                       DR to clomi or SSRIs with dose unchanged randomised × 6 wk to add-on olanzapine or placebo                                                                                                                                                                                                                                                    Effect: % ↓Y-BOCS; Response: Y-BOCS ↓≥25% from BL                                                                                                                                                                                      -1.99% (↑Y-BOCS from BL)                                  0% (↓≥25% Y-BOCS)                                                                    Full-dose clomi, fluoxetine, sertraline, paroxetine;\                                                                                                                                                                     17.36% (↓Y-BOCS from BL)                                            46% (↓≥25% Y-BOCS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    add-on olanzapine 2.5 → 5-20 mg/day                                                                                                                                                                                                                                                           

  Denys *et al*. \[[@r73]\]                                  2004       Rudolf Magnus Institute of Neuroscience (DD), Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands                                                                                                                                         20 DR to SSRIs to add-on placebo; 20 to add-on quetiapine                                                                                                                                                                                   DR to SSRIs (failure to achieve ↓≥25% of Y-BOCS scores from BL) randomised to add-on quetiapine *vs*. placebo × 8 wk                                                                                                                                                                                                                          Y-BOCS (response ↓≥35% drop from BL); CGIi 1-2                                                                                                                                                                                         6.8% Y-BOCS; 7,5% CGIi                                    10% CGIi                                                                             Various SSRIs at various doses plus quietapine (B) 200-300 mg/day                                                                                                                                                         31.9% Y-BOCS\                                                       40% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              27,5% CGIi                                                          

  Fux *et al*. \[[@r74]\]                                    2004       BeerSheva Mental Health Center, Ben Gurion University of the Negev, Beer-Sheva, Israel                                                                                                                                                                                      11 with unsatisfactory response to SSRI during last 2 months: 5 placebo add-on *vs*. 6 EPA add-on                                                                                                                                           Cross-over RCT, EPA *vs.* placebo added-on highest tolerated SSRI dose                                                                                                                                                                                                                                                                        Response criteria not specified; assessment performed with Y-BOCS                                                                                                                                                                      32.3%                                                                                                                                          Various SSRIs at various doses; EPA 2g/day                                                                                                                                                                                28.8%                                                               

  Geller *et al*. \[[@r75]\]                                 2004       Pediatric OCD Clinic, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA                                                                                                                                                                               203 (7-17 years); 105 placebo *vs*. 98 paroxetine                                                                                                                                                                                           Multicentre (34 sites); paroxetine *vs*. placebo × 10 wk                                                                                                                                                                                                                                                                                      Effect: ↓CY-BOCS score from BL;\                                                                                                                                                                                                       21.1%                                                     41.2%                                                                                Paroxetine 10-50 mg/die                                                                                                                                                                                                   36%                                                                 64.9%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: ↓≥25% CY-BOCS from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Kamijima *et al*. \[[@r76]\]                               2004       Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan                                                                                                                                                                                                             188; 94 placebo *vs*. 94 paroxetine                                                                                                                                                                                                         Multicentre (? sites), DB paroxetine *vs*. placebo × 12 wk                                                                                                                                                                                                                                                                                    Effect: ↓Y-BOCS scores from BL; response: ↓≥25% Y-BOCS from BL; CGIi 1-2                                                                                                                                                               14.8% Y-BOCS                                              23.7% CGIi                                                                           Paroxetine 20-50 mg/day                                                                                                                                                                                                   33.4% Y-BOCS                                                        50% CGIi

  Shapira *et al*. \[[@r77]\]                                2004       Department of Psychiatry, University of Florida, College of Medicine, Gainesville, FL, USA                                                                                                                                                                                  44 partial/non responders to fluoxetine, 22 placebo *vs*. 22 add-on olanzapine                                                                                                                                                              DR (partial/non-responders, *i.e*., \<↓25% Y-BOCS score from BL or \<16 total Y-BOCS or symptomatic) to 8-wk double-blind fluoxetine randomised × 6 wk to add-on olanzapine or placebo                                                                                                                                                        Treatment effect: % ↓Y-BOCS scores from BL; Response: Y-BOCS ↓≥25% from BL                                                                                                                                                             3.8%                                                      41% ↓≥25% from BL; (18% ↓≥35% Y-BOCS from BL)                                        Fluoxetine 40 mg/day; Olanzapine 5-10 mg/day                                                                                                                                                                              5.1%                                                                41% ↓≥25% from BL; (23% ↓≥35% Y-BOCS from BL)

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  The Pediatric OCD Treatment Study (POTS) Team \[[@r78]\]   2004       Department of Psychiatry, Duke University Medical College, Durham, NC, USA                                                                                                                                                                                                  112 children and adolescents (7-17 yrs.) CY-BOCS≥16; 28 placebo *vs*. 28 sertraline *vs*. 28 CBT *vs*. 28 sertraline + CBT placebo                                                                                                          Multicentre (3 sites), balanced, masked RCT (biased by patient preference) of sertraline *vs*. CBT *vs*. sertraline + CBT *vs*. placebo × 12 wk                                                                                                                                                                                               Effect:\                                                                                                                                                                                                                               14.68%                                                    3.6%                                                                                 Sertraline 25→max200 mg/day;\                                                                                                                                                                                             29.79%\                                                             21.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ↓CY-BOCS from BL; Response: CY-BOCS≥10                                                                                                                                                                                                                                                                                                                                                14 CBT sessions with psychoeducation, cognitive training mapping OCD target symptoms and ERP;\                                                                                                                            \                                                                   \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sertraline + CBT                                                                                                                                                                                                          46.15%\                                                             39.3%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \                                                                   \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              52.84%                                                              \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  53.6%

  Carey *et al*. \[[@r79]\]                                  2005       MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa                                                                                                                                                                                 42 SSRI-resistant patients defined as not responding to at least two adequate trials (12 wks); 21 SSRI+placebo, 20 SSRI+ quetiapine                                                                                                         Multicentre RCT (5 sites); DR (CGI≥3 or ↓Y-BOCS ≤25% from before treatment) to SSRI randomised to add-on quetiapine *vs*. placebo × 6 wk                                                                                                                                                                                                      Treatment effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                             26%\                                                      47.6%                                                                                Various SSRIs at various doses;\                                                                                                                                                                                          26.9%\                                                              40%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response:\                                                                                                                                                                                                                             Y-BOCS\                                                                                                                                        Add-on quetiapine,\                                                                                                                                                                                                       Y-BOCS\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ↓Y-BOCS ≥25% from BL\                                                                                                                                                                                                                  22.6%\                                                                                                                                         ≈200 mg/day                                                                                                                                                                                                               21,1%\                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *and* CGIi 1-2                                                                                                                                                                                                                         CGIi                                                                                                                                                                                                                                                                                                                                                                     CGIi                                                                

  Erzegovesi *et al*. \[[@r80]\]                             2005       Department of Neurosciences, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy                                                                                                                                                                       39 patients stabilised on fluvoxamine 150-300 mg/day; 19 placebo *vs*. 20 add-on risperidone; 20 DR (10 placebo; 10 risperidone) and 19 responders (9 placebo; 10 risperidone)                                                              DR to fluvoxamine (failure to reach ↓≥35% drop from BL Y-BOCS score) and responders to open fluvoxamine randomised × 6 wk to add-on risperidone or placebo                                                                                                                                                                                    Y-BOCS scores (response ↓≥35% drop from BL);\                                                                                                                                                                                          13.89%;\                                                  Non-resp 20% Y-BOCS                                                                  Fluvoxamine 150-300 mg/die; risperidone 0.5 mg/die                                                                                                                                                                        18.24%;\                                                            Non-responders, 50%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (Responders and non-responders here refer to open fluvoxamine and *not* to the add-on)                                                                                                                                                 Responders 27.63%; Non-responders: 6.82% Y-BOCS                                                                                                                                                                                                                                                                                                                          Responders, 3.82%; non-responders, 25.57%                           

  Fineberg *et al*. \[[@r81]\]                               2005       Department of Psychiatry, Queen Elizabeth II Hospital, Hertfordshire, Welwyn Garden City, Department of Psychology, University of Hertfordshire, Hatfield, UK                                                                                                               21 DR (Y-BOCS ≥18 and ↓≥25% Y-BOCS after ≥12 wks SSRI at max tolerated dose); 10 placebo, 11 quetiapine add-on                                                                                                                              Add-on of quetiapine *vs*. placebo × 16 wk on stable SSRI at max tolerated dose                                                                                                                                                                                                                                                               Effect: %↓Y-BOCS from BL;\                                                                                                                                                                                                             6%                                                        10%                                                                                  Quetiapine 25→max 400 mg/die + SSRI (citalopram, sertraline, paroxetine)                                                                                                                                                  14%                                                                 27.27%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              response ↓≥25% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Foa *et al*. \[[@r82]\]                                    2005       Center for the Treatment and Study of Anxiety, University of Pennsylvania, Philadelphia, PA, USA                                                                                                                                                                            122, 26 placebo *vs*. 36 clomi, *vs*. 29 ERP, *vs*. 31 clomi + ERP                                                                                                                                                                          Multicentre (3 centres), 12-wk RCT; Clomi *vs.* placebo *vs*. ERP *vs*. clomi + ERP                                                                                                                                                                                                                                                           Effect: ↓Y-BOCS from BL\                                                                                                                                                                                                               11.2% Y-BOCS\                                             8%                                                                                   Clomi 200 mg/day\                                                                                                                                                                                                         30.7% Y-BOCS; 19.6% CGIi\                                           41.67%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: CGIi \<3                                                                                                                                                                                                                     6% CGIi                                                                                                                                        ERP: 2h exposure sessions, 5 times a week + daily exposure and ritual prevention homework max 2h\                                                                                                                         55.28% Y-BOCS; 43.75% CGI\                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Combined Clomi + ERP                                                                                                                                                                                                      58.66% Y-BOCS; 40.82 CGIi                                           \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  62.07%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  67.74%

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Kobak *et al*. \[[@r83]\]                                  2005       Dean Foundation For Health, Research and Education, Middleton, WI, USA                                                                                                                                                                                                      60 with Ham-D \<16; 30 placebo *vs*. 30 St. John's wort *(Hypericum perforatum)*                                                                                                                                                            Multicentre (4 sites), DB CRT of flexible *Hypericum* or placebo × 12 wk                                                                                                                                                                                                                                                                      Effect: ↓Y-BOCS scores from BL; response: CGIi 1-2                                                                                                                                                                                     20.665% Y-BOCS                                            16.7% CGIi                                                                           Hypericum perforatum (Saint John's wort) flexible doses 600→1800 mg/day                                                                                                                                                   23.306% Y-BOCS                                                      17.9% CGIi

  Koran *et al*. \[[@r84]\]                                  2005       Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA, USA                                                                                                                                                                     23 DR with OCD since at least 3 years, with Y-BOCS ≥20 and poor response to at least two SSRI trials (≥8 wks at full dose); 32 placebo                                                                                                      Add-on to stable antidepressant therapy of morphine, lorazepam or placebo × 7 wk: 2 wk of each in random order; cross-over, but only first part considered (prior to cross-over)                                                                                                                                                              Effect: ↓Y-BOCS score\                                                                                                                                                                                                                 7%                                                        0%                                                                                   Morphine 30 mg/week 1 →15-45 mg/week adjustment\                                                                                                                                                                          27%\                                                                30.43%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS (response ↓≥25% from BL)                                                                                                                                                                                                                                                                                                                                             Lorazepam 1 mg →0.5-2 mg/week                                                                                                                                                                                             \                                                                   \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \                                                                   \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \                                                                   \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              6%                                                                  17.4%

  Li, X. *et al*. \[[@r85]\]                                 2005       Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA                                                                                                                                                              13 DR to ≥12-wk SSRIs (symptomatic; ≥10 score on Y-BOCS items 1-5; ≥16 total Y-BOCS score); 5 placebo first, 5 haloperidol first, 3 risperidone first                                                                                       DB cross-over of DR on stable antidepressant, randomised × 9 wk to add-on risperidone, haloperidol or placebo (1 wk placebo→2 wk placebo or haloperidol or risperidone→1 wk placebo→2 wk cross-over→ 1wk placebo→ 2 wk cross-over)                                                                                                            Effect: ↓Y-BOCS from BL; no criteria for response                                                                                                                                                                                      23.96%                                                                                                                                         ≥40 mg fluoxetine, ≥200 mg fluvoxamine, ≥100 mg sertraline; dose unaltered during trial;\                                                                                                                                 48.62%\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    add-on haloperidol 2 mg/day\                                                                                                                                                                                              \                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    risperidone 1 mg/day                                                                                                                                                                                                      \                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              36.29%                                                              

  Nakatani *et al*. \[[@r86]\]                               2005       Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan                                                                                                                                                                       28 DR; 8 placebo + autogenic training *vs*. 10 behaviour therapy + placebo *vs*. 10 fluvoxamine + autogenic training                                                                                                                        DR patients assigned to one of three groups: behavioural therapy + placebo; fluvoxamine + autogenic training; autogenic training + placebo ×12 wk                                                                                                                                                                                             Y-BOCS scores (response ↓≥35% from BL), CGIi 1-2; responsiveness to placebo was taken as the response of Y-BOCS scores and the CGIi criterion of the placebo + autogenic training group                                                6.88%                                                     0%                                                                                   Fluvoxamine 150-200 mg/day                                                                                                                                                                                                28.87%                                                              30%

  Buchsbaum *et al*. \[[@r87]\]                              2006       Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                                                           16 DR, 6 placebo *vs*. 10 risperidone                                                                                                                                                                                                       DR to clomi, fluvoxamine, sertraline, fluoxetine, paroxetine, citalopram, and venlafaxine randomised double-blind ×8 wk to add-on risperidone or placebo                                                                                                                                                                                      Response: Y-BOCS ↓≥25% from BL; CGIi 1-2                                                                                                                                                                                               4.53%                                                     0% (CGIi) 0% (Y-BOCS)                                                                Actual minimum daily doses: 200 mg clomi, 60 fluoxetine, 150 fluvoxamine, 150 sertraline, 60 citalopram, 325 venlafaxine;\                                                                                                20.89%                                                              40% (CGIi) 40% (Y-BOCS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    add-on risperidone 0.5 → 3 mg/day                                                                                                                                                                                                                                                             

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  O'Connor *et al*. \[[@r88]\]                               2006       Fernand-Seguin Research Centre, Louis-H. Lafontaine Hospital, Montreal, QC, Canada                                                                                                                                                                                          21 with Y-BOCS \>16; 10 placebo *vs.* 11 fluvoxamine (first protocol); thereafter, 43 (comprising the first 21) received CBT *vs*. 10 CBT alone, *vs*. 12 CBT + stabilised on antidepressant                                                DB, random allocation to fluvoxamine *vs*. placebo ×5 months (first protocol); after conclusion or stabilisation (on or off-drug) of another population, all receive CBT; CBT to drug naïve patients, CBT + stabilised on drug, CBT to previous placebo group, CBT to previous fluvoxamine group × 5 months (20 sessions) (second protocol)   Treatment effect: ↓Y-BOCS scores Response: \>↓35% Y-BOCS from BL                                                                                                                                                                       6.96% Y-BOCS                                              0%                                                                                   Fluvoxamine 100 → max 300 mg/day;\                                                                                                                                                                                        15.19%\                                                             9%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CBT -- ERP 1 weekly session for a total of 20 over 5 months;\                                                                                                                                                             \                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CBT + fluvoxamine                                                                                                                                                                                                         53.33%\                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (not used in analyses)\                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              42.69% Y-BOCS (not used in analyses)                                

  Fineberg *et al*. \[[@r89]\]                               2007       Postgraduate Medical School, University of Hertfordshire, Hatfield, UK                                                                                                                                                                                                      320 responders to 16-wk 10 or 20 mg escitalopram with Y-BOCS ↓≥25% from BL; 157 placebo *vs.* 163 escitalopram 10 or 20 mg/day                                                                                                              Multicentre (62 sites), multi-national (14 countries), DB RCT escitalopram 10 *vs*. 20 *vs*. placebo × 24 wk                                                                                                                                                                                                                                  No relapse, defined as either an increase in Y-BOCS scores ≥5 from randomisation or as unsatisfactory treatment effect (lack of efficacy) judged by investigator;\                                                                     48% no relapse                                            72% Y-BOCS                                                                           Escitalopram fixed dose 10mg/die or 20mg/die                                                                                                                                                                              77% no relapse                                                      90% Y-BOCS
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Responders: Y-BOCS ↓≥25% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Stein *et al*. \[[@r90]\]                                  2007       University of Cape Town, Department of Psychiatry, Groote Schuur Hospital, Cape Town, South Africa                                                                                                                                                                          458; 114 placebo *vs*. 113 escitalopram 10, 114 escitalopram 20, 117 paroxetine                                                                                                                                                             Double-blind randomized fixed-dose escitalopram × 24 wk to paroxetine or placebo                                                                                                                                                                                                                                                              Primary outcome: ↓Y-BOCS from BL at week 12; secondary: mean Y-BOCS change from BL at week 24;\                                                                                                                                        wk12: 30.54% wk24: 38.51% Y-BOCS                          wk12 38.5%; wk24 38% (CGIi); wk12 52%; wk24 50% (Y-BOCS)                             Escitalopram 10 mg/die or\                                                                                                                                                                                                wk12: 42.97%\                                                       wk12 50% wk24 58% (CGIi)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: Y-BOCS **≤**10\                                                                                                                                                                                                                                                                                                                                                            \                                                                                                                                                                                                                         wk24: 51.77%\                                                       wk12 66% wk24 63% (Y-BOCS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: CGIi 1 or 2; Y-BOCS ↓≥25% from BL                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                                                                                                         \                                                                   wk12 56% wk24 58.5% (CGIi)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Escitalopram 20 mg/die or\                                                                                                                                                                                                wk12: 45.64\                                                        wk12 70.5% wk24 70.5% (Y-BOCS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                                                                                                                                                                                         wk24: 51.84%\                                                       wk12 54% wk24 58% (CGIi)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                                                                                                                                                                                         \                                                                   wk12 65% wk24 67% (CGIi)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                                                                                                                                                                                         \                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Paroxetine 40 mg/die                                                                                                                                                                                                      wk12: 42.75\                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              wk24: 54.62%                                                        

  Amiaz *et al*. \[[@r91]\]                                  2008       Division of Psychiatry, Chaim Sheba Medical Center, Tel-Hashomer, Israel                                                                                                                                                                                                    10 DR to SSRIs or clomi ×2 months; 5 placebo first, 5 naltrexone first                                                                                                                                                                      DB cross-over of DR patients to ≥2-month clomi or 2 SSRIs × 5 wk to add-on naltrexone or placebo, × 1 wk to add-on placebo only × 5 wk to cross-over add-on naltrexone or placebo                                                                                                                                                             Treatment effect: ↓Y-BOCS score from BL; ↓CGIs from BL; no response criteria provided                                                                                                                                                  5.46% (↓Y-BOCS);\                                                                                                                              Stable SSRI or clomi;\                                                                                                                                                                                                    -16.07% (↑Y-BOCS scores);\                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     18.42% (↓CGIs)                                                                                                                                 add-on naltrexone 50 → 100 mg/die                                                                                                                                                                                         -10.7% (↑CGIs scores)                                               

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Kordon *et al*. \[[@r92]\]                                 2008       Department of Psychiatry and Psychotherapy, University of Luebeck, Luebeck, Germany                                                                                                                                                                                         40 DR; 20 placebo *vs*.20 add-on quetiapine                                                                                                                                                                                                 Multicentre (2 sites), DR to SSRI or clomi × 12 wk (failure to reach ↓≥25% drop from BL Y-BOCS scores) randomised to add-on quetiapine or placebo                                                                                                                                                                                             Y-BOCS (response ↓≥35% drop from BL);\                                                                                                                                                                                                 15.1% Y-BOCS                                              30% CGIi                                                                             SSRI or clomi at fixed dose; Quietiapine 400-600 mg/day                                                                                                                                                                   21.6% Y-BOCS                                                        22% CGIi
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              CGIi 1-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Greenberg *et al*. \[[@r93]\]                              2009       New York University School of Medicine, Department of Psychiatry, New York, NY, USA                                                                                                                                                                                         13 DR (drugs or psychotherapy), with treatment stabilised ×≥12wks, 9 placebo *vs*. 5 glycine add-on                                                                                                                                         DB RCT 1:1 of DR to add-on glycine *vs*. placebo × 12 wk to unchanged regimen (drugs and/or psychotherapy)                                                                                                                                                                                                                                    Effect: ↓Y-BOCS score from BL; ↓NIMH-OC score from BL;↓CGIs score from BL;\                                                                                                                                                            4.04% (Y-BOCS);\                                          0% (Y-BOCS plus CGIi)                                                                Glycine powder dissolved in water plus flavour enhancer → 60 g/day added on stabilised treatment (drug and/or psychotherapy)                                                                                              24.59% (Y-BOCS);\                                                   40% (Y-BOCS plus CGI)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL *and* CGIi 1-2                                                                                                                                                                                          2.44% NIMH-OC;\                                                                                                                                                                                                                                                                                                                                                          22.22% NIMH-OC;\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2.36% (CGIs)                                                                                                                                                                                                                                                                                                                                                             13.04% (CGIs)                                                       

  Sayyah *et al*. \[[@r94]\]                                 2009       Department of Psychiatry, Joondi Shapoor University of Medical Sciences, Ahwaz, Iran                                                                                                                                                                                        44 with Y-BOCS≥21; 20 placebo *vs*. 24 aqueous extract of *Echium amoenum*                                                                                                                                                                  DB, RCT of 500 mg aqueous extract of *Echium amœnum* × 6 wk                                                                                                                                                                                                                                                                                   Effect: ↓Y-BOCS scores from BL\                                                                                                                                                                                                        11.31% Y-BOCS                                                                                                                                  125 mg aqueous extract of *Echium amoenum* capsules: 1 morning; 1 afternoon, 2 night                                                                                                                                      25.55% Y-BOCS                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: not provided                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Mowla *et al*. \[[@r95]\]                                  2010       Department of Psychiatry, Bushehr University of Medical Sciences, Bushehr, Iran                                                                                                                                                                                             41 Y-BOCS≥18 to:\                                                                                                                                                                                                                           12-wk, double-blind, placebo-controlled, randomized trial of 200 mg/day topiramate *vs*. placebo                                                                                                                                                                                                                                              Treatment effects: ↓Y-BOCS from BL; response: Y-BOCS ↓≥25% from BL (after 12 weeks)                                                                                                                                                    2.4% (↓Y-BOCS)                                            0% (Y-BOCS ↓≥25% from BL)                                                            Topiramate (initially 25 mg/day, increased in 25-mg increments weekly to a target dose of 200 mg/day                                                                                                                      32% (↓Y-BOCS);                                                      60% (Y-BOCS ↓≥25% from BL)
                                                                                                                                                                                                                                                                                                                                                    -*N*=20 Topiramate;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                    or\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                    -*N*=21 placebo; × 12 wks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Storch *et al*. \[[@r96]\]                                 2010       Department of Pediatrics, Rothman Center for Neuropsychiatry, University of South Florida, St. Petersburg, FL, USA                                                                                                                                                          30 children and adolescents with OCD (Range 8-17 years); 15 placebo, 15 D-cycloSer                                                                                                                                                          DB RCT of CBT + D-cycloSer *vs*. CBT + Placebo × 8 wk (10 sessions). 1:1 randomisation                                                                                                                                                                                                                                                        Effect: % ↓ CGI-S, CYBOCS, and ADIS-CSR from BL.\                                                                                                                                                                                      41% (↓CGI-S), 58% (↓ CY-BOCS), 53% (↓ADIS-CSR)                                                                                                 25 or 50 mg of D-cycloSer (depending on patient weight) 1 h before psychotherapy, sessions 4-10                                                                                                                           57%(↓CGI-S)\                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              no criterion for response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       72%\                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (↓ CYBOCS)\                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              71% (↓ADIS-CSR)                                                     

  Sayyah *et al*. \[[@r97]\]                                 2011       Education Development Center (EDC), Jundishapur University of Medical Sciences, Ahwaz, Iran                                                                                                                                                                                 52 drug naïve OCD patients randomised to celecoxib (*N*=27) or placebo (*N*=25)                                                                                                                                                             DB RCT of fluoxetine 20 mg/day + celecoxib 400 mg/day *vs*. fluoxetine 20 mg/day + placebo × 8 wk                                                                                                                                                                                                                                             Effect: % ↓Y-BOCS score from BL; no criterion for response                                                                                                                                                                             46.7% (↓Y-BOCS)                                                                                                                                Fluoxetine 20 mg/day + Celecoxib 400 mg/day                                                                                                                                                                               66.2% (↓Y-BOCS)                                                     

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Muscatello *et al*. \[[@r98]\]                             2011       Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, IRCCS Centro Neurolesi "Bonino-Pulejo" University of Messina, Messina, Italy   30 Y-BOCS≥18 to\                                                                                                                                                                                                                            16-wk, open-label. flexible-dose (up to 30 mg/day), pilot trial                                                                                                                                                                                                                                                                               Treatment effects: ↓Y-BOCS score from BL; partial response (pr): Y-BOCS ↓≥25% from BL; complete response (cr): Y-BOCS ↓≥35% from BL; remission (r) (Y-BOCS ≤16 after 16 weeks)                                                         -2.54% (↓Y-BOCS)                                          0% (pr); 0%\                                                                         Aripiprazole 15 mg/day added to SSRI                                                                                                                                                                                      28.5% (↓Y-BOCS);                                                    43.7% (pr); 25% (cr)
                                                                                                                                                                                                                                                                                                                                                    N=16 aripripazole (15 mg/day)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (cr)                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                    N=14 Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Berlin *et al*. \[[@r99]\]                                 2011       Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA                                                                                                                                                                                             36 OCD patients with Y-BOCS ≥ 18; 18 randomised to placebo and 18 to topiramate                                                                                                                                                             DB RCT of add-on topiramate (up to 400 mg/d) over continuing SSRI vs. placebo plus SSRIs × 12 wk                                                                                                                                                                                                                                              Effect: % ↓Y-BOCS score from BL after 12 weeks. No response criteria                                                                                                                                                                   16% (↓Y-BOCS from BL to 12 weeks)                                                                                                              Add-on topiramate titrated over 8 weeks up to 400 mg/day or maximum tolerated dose                                                                                                                                        38% (↓Y-BOCS)                                                       

  Pakseresht *et al*. \[[@r100]\]                            2011       Jundishapur University of Medical Sciences, Ahwaz, Iran                                                                                                                                                                                                                     31 (18-60 y) to\                                                                                                                                                                                                                            8-wk double-blind, parallel-group, randomised trial                                                                                                                                                                                                                                                                                           Treatment effect: ↓Y-BOCS from BL after 8 weeks; no response criteria provided                                                                                                                                                         23.3% (↓Y-BOCS);                                                                                                                               Valeriana Root (Valeriana Officinalis L.) 750 mg/day in three divided doses                                                                                                                                               43.3% (↓Y-BOCS)                                                     
                                                                                                                                                                                                                                                                                                                                                    -N=15 extract of *Valeriana Officinalis L*. (765 mg/day)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                    or\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                    -N=16 placebo (30 mg/day)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                    × 8 wks\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                    (Y-BOCS≥21)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Sayyah *et al*. \[[@r101]\]                                2012       Jundishapur University of Medical Sciences, Ahwaz, Iran                                                                                                                                                                                                                     23 drug naïve OCD patients; add-on to fluoxetine, 12 ZnSO~4~, 11 placebo                                                                                                                                                                    DB RCT of 20 mg/day fluoxetine + 440 mg/day ZnSO~4~ *vs*. 20 mg/day fluoxetine + placebo × 8 wk                                                                                                                                                                                                                                               Effect: % ↓Y-BOCS score from BL.\                                                                                                                                                                                                      46.84% (↓Y-BOCS)                                                                                                                               20 mg/day Fluoxetine + 440 ZnSO~4~ mg/day                                                                                                                                                                                 54.54% (↓Y-BOCS)                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              no criterion for response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Sayyah *et al*. \[[@r102]\]                                2012       Imam General Hospital, Jundishapur University of Medical Sciences, Ahwaz, Iran                                                                                                                                                                                              32 adult outpatients:\                                                                                                                                                                                                                      12-wk, double-blind RCT                                                                                                                                                                                                                                                                                                                       Treatment effects: ↓Y-BOCS score from BL; response: Y-BOCS ↓≥25% after 12 weeks                                                                                                                                                        17.6% (↓Y-BOCS);                                          8.3% (Y-BOCS ↓≥25% after 12 weeks)                                                   Aripiprazole 10 mg/day                                                                                                                                                                                                    29.5% (↓Y-BOCS);                                                    53% (Y-BOCS ↓≥25% after 12 weeks)
                                                                                                                                                                                                                                                                                                                                                    N=15 10 mg/day aripiprazole\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                    N=17 placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Afshar *et al*. \[[@r103]\]                                2012       Nour Hoospital, Psychosomatic Research Center, Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran                                                                                                                          48 DR OCD patients (SSRI/clomi non-responders); 19 *N*AC, 20 placebo                                                                                                                                                                        DB RCT of add-on →2400 mg/day *N*AC *vs*. placebo ×12 wk                                                                                                                                                                                                                                                                                      Effect: % ↓Y-BOCS score from BL. % ↓ CGI-S from BL\                                                                                                                                                                                    20.7% (↓Y-BOCS)\                                          Response: 15%; No data on partial response                                           Initial dosage of 600 mg/d of *N*AC, which doubled weekly to a maximum dose of 2400 mg/d                                                                                                                                  39.2% (↓Y-BOCS); 24.9% (↓CGIs)                                      Response: 52.6%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL;\                                                                                                                                                                                               10.4% (↓CGIs)                                                                                                                                                                                                                                                                                                                                                                                                                                No data on partial response given
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Bruno *et al*. \[[@r104]\]                                 2012       Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Messina, Italy                                                                                                                                      33 DR OCD patients (persistent obsessive-compulsive symptoms: despite adequate SSRI trial(s) → Y-BOCS ≥16); 17 lamotrigine, 16 placebo                                                                                                      DB RCT of add-on lamotrigine 100 mg/day vs placebo for 16 wk                                                                                                                                                                                                                                                                                  Effect: % ↓Y-BOCS score from BL;\                                                                                                                                                                                                      -1.2% (↓Y-BOCS)                                           Response: 0%                                                                         Add-on lamotrigine increased from 25 mg/day to\                                                                                                                                                                           33.8% (↓Y-BOCS)                                                     Partial response: 50%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL;\                                                                                                                                                                                                                                                                                                                                              100 mg/day at week 4, in increments of 25 mg/week Maximum dose of 100 mg maintained until the end of the trial                                                                                                                                                                                Complete response: 35%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Askari *et al*. \[[@r105]\]                                2012       Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran                                                                                                                                                                          39 drug naïve OCD patients (Y-BOCS ≥21) randomised to placebo (*N*=20) or granisetron (*N*=19)                                                                                                                                              Multicentre DB RCT of fluvoxamine 100-200 mg/day + granisetron 2 mg/day *vs*. fluvoxamine 100 - 200 mg/day + placebo × 8 wk                                                                                                                                                                                                                   Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       34.7% (↓Y-BOCS)                                           Partial response: 35%; Complete response: 35%; Remission: 35%                        Fluvoxamine 100 mg/day × first 4 weeks, 200 mg/day × next 4 weeks + granisetron 2 mg/day                                                                                                                                  59.1% (↓Y-BOCS)                                                     Partial response: 100%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Complete response: 100%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Remission: 90%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: Y-BOCS ≤ 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Ghaleiha *et al*. \[[@r106]\]                              2013       Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, Iran                                                                                                                                                         38 patients with diagnosis of OCD and Y-BOCS score ≥21 randomised to add-on placebo (*N*=19) or memantine (*N*=19)                                                                                                                          DB RCT of fluvoxamine + memantine *vs*. fluvoxamine + placebo × 8 wk                                                                                                                                                                                                                                                                          Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       36.9% (↓Y-BOCS)                                           Partial or complete\                                                                 Memantine 10 mg/day for\                                                                                                                                                                                                  57,9% (↓Y-BOCS)                                                     Partial or complete\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL\                                                                                                                                                                                                                                                          response: 32%\                                                                       the first week of the trial, then 20 mg/day                                                                                                                                                                                                                                                   response: 100%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL\                                                                                                                                                                                                                                                                  Remission: 32%                                                                                                                                                                                                                                                                                                                                                                     Remission: 89%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: Y-BOCS ≤16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Storch *et al*. \[[@r107]\]                                2013       Department of Pediatrics, University of South Florida,\                                                                                                                                                                                                                     47 children and adolescents with OCD (Range 7-17 years) randomised to RegSert (*N*=14), SloSert (*N*=17) or placebo (*N*=16) + CBT for all                                                                                                  DB RCT of sertraline at standard dosing + CBT or sertraline titrated slowly + CBT or placebo + CBT × 18 wk. Patients randomized in a 1:1:1 fashion.                                                                                                                                                                                           Effect: % ↓CY-BOCS score from BL.\                                                                                                                                                                                                     37.9% (↓Y-BOCS)                                           Response: 62.5% (CY-BOCS ↓≥30% from BL)\                                             RegSert: upward titration from 25 mg/day to 200 mg/day in 5 wk.\                                                                                                                                                          RegSert: 34.7% (↓Y-BOCS)\                                           Response: 57.1% for RegSert + CBT; 64.7% for SloSert + CBT; Remission: 42.9% for RegSert + CBT; 23.5% for SloSert + CBT
                                                                        St. Petersburg, FL, USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Response: CY-BOCS ↓≥30% from BL\                                                                                                                                                                                                                                                                 Remission: 18.8% (CY-BOCS score below 10)                                            SloSert: upward titration from 25 mg/day to 200 mg/day in 9 wk                                                                                                                                                            SloSert: 35.5% (↓Y-BOCS)                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: CY-BOCS score \<10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Haghighi *et al*. \[[@r108]\]                              2013       Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran                                                                                                                                                        29 inpatients with diagnosis of OCD and Y-BOCS score ≥21 despite treatment with SSRI or clomi to: memantine (*N*=14) or placebo (*N*=15)                                                                                                    DB RCT of add-on memantine 5--10 mg/day *vs*. placebo × 12 wk                                                                                                                                                                                                                                                                                 Effect: % ↓Y-BOCS score from BL. % ↓ CGI-S from 4^th^ week; Partial response: Y-BOCS ↓≥25% from BL; Response: Y-BOCS ↓≥35% from BL                                                                                                     15.8% (↓Y-BOCS)\                                          Partial or complete response: 26.6%                                                  Add-on memantine 5--10 mg/day                                                                                                                                                                                             32.2% (↓Y-BOCS) 30.2% (↓CGIs)                                       Partial or complete response: 92.8%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     13.4% (↓CGIs)                                                                                                                                                                                                                                                                                                                                                                                                                                

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Storch *et al*. \[[@r109]\]                                2013       Department of Pediatrics, Rothman Center for Neuropsychiatry, University of South Florida,\                                                                                                                                                                                 34 DR OCD patients (Y-BOCS≥ 19 despite at least 2 adequate SSRI trials) randomised to placebo (*N*=17) or paliperidone (*N*=17)                                                                                                             DB RCT of add-on Paliperidone (up to 9 mg/d) *vs*. placebo × 8 wk                                                                                                                                                                                                                                                                             Effect: % ↓Y-BOCS score from BL.\                                                                                                                                                                                                      15.7% (↓Y-BOCS)\                                          Response: 29%\                                                                       Add-on Paliperidone starting from 3 mg/day and titrated up to 9 mg/day by week 6 unless not tolerated                                                                                                                     29.4% (↓Y-BOCS) 20.1% (↓CGI-S)                                      Response: 35% (Y-BOCS ↓≥35%)\
                                                                        St. Petersburg, FL, USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               %↓CGI-S from BL\                                                                                                                                                                                                                       18.7% (↓CGI-S)                                            (Y-BOCS ↓≥35%) 18% (CGIi =1/2)                                                                                                                                                                                                                                                                                                                                                     35% (CGIi=1/2)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              CGI-i = 1 - 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Rodriguez *et al*. \[[@r110]\]                             2013       New York State Psychiatric Institute, New York, NY, USA; Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY, USA                                                                                                               15 drug free OCD patients with Y-BOCS ≥ 16 who had failed at least one prior SSRI trial and/or CBT: 8 to ketamine and 7 to placebo                                                                                                          DB Crossover RCT of iv ketamine (0.5 mg/kg) *vs*. iv saline spaced at least 1-wk apart                                                                                                                                                                                                                                                        Effect: ↓OCD-VAS Response: Y-BOCS ↓≥35% from BL                                                                                                                                                                                        7.2% (↓OCD-VAS)                                           Response: 0%                                                                         Intravenous infusion of ketamine (0.5 mg/kg) over 40 min                                                                                                                                                                  45.4% (↓OCD-VAS)                                                    Response: 50%

  Simpson *et al*. \[[@r111]\]                               2013       Department of Psychiatry, Columbia University, New York State Psychiatric Institute, New York, NY, USA                                                                                                                                                                      100 patients on SSRI with still clinically significant OCD (Y-BOCS ≥ 16); 97 patients to\                                                                                                                                                   RCT comparing SSRI augmentation with either EX/RP therapy, risperidone (→ max 4.0 mg/d), or pill placebo × 8 wk in two centres                                                                                                                                                                                                                Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       10.81% (↓Y-BOCS)                                          Responders: 15%\                                                                     Add-on risperidone (up to 4 mg/day)\                                                                                                                                                                                      EX/RP: 52.2% (↓Y-BOCS). Risperidone: 13.4% (↓Y-BOCS)                EX/RP response: 80%\
                                                                                                                                                                                                                                                                                                                                                    *N*=38 Risperidone (up to 4 mg/d)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Response: Y-BOCS ↓≥25% from BL                                                                                                                                                                                                                                                                   (Y-BOCS ↓≥25%)                                                                       EX/RP (17, 2×week, 90 min-sessions)                                                                                                                                                                                                                                                           Risperidone response: 22.5%
                                                                                                                                                                                                                                                                                                                                                    *N*=40 EX/RP (17 session, 2 wkly)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                    *N*=19 placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Park *et al*. \[[@r112]\]                                  2014       Department of Psychology, University of South Florida,\                                                                                                                                                                                                                     30 children and adolescents with OCD (CY-BOCS≥16) stable on psychotropic medication × ≥ 12 wks: 15 to D-cycloSer; 15 to placebo                                                                                                             DB RCT of ERP + D-cycloSer (25-50 mg) after last 7 sessions *vs*. ERP + placebo × 10 wk                                                                                                                                                                                                                                                       Effect: %↑ Homework compliance (rated with a 7-point Likert scale ranging from 0 ("did not complete any assigned homework") to 6 ("completed all homework and made efforts above and beyond assignments"); no criterion for response   4.7% (↑ homework compliance)                                                                                                                   Exposure and response prevention therapy (ERP) + D-cycloSer (25-50 mg depending on weight) after last 7 session                                                                                                           -6% (↑ homework compliance)                                         
                                                                        Tampa, FL, USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Grant *et al*. \[[@r113]\]                                 2014       Pediatrics and Developmental Neuroscience Branch, NIMH, National Institutes of Health, Bethesda, MD, USA                                                                                                                                                                    60 treatment-resistant children and adolescents (7-17 years, CY-BOCS≥20); 30 to riluzole, 30 to placebo                                                                                                                                     DB RCT of add-on riluzole (up to 100 mg/day) *vs*. placebo × 12 wk                                                                                                                                                                                                                                                                            Effect: % ↓CY-BOCS score from BL.\                                                                                                                                                                                                     22.9% (↓CY-BOCS)\                                         Response: 18%                                                                        Add-on riluzole starting from 10 mg/day and increased daily up to 100 mg/day                                                                                                                                              20.1% (↓CY-BOCS)\                                                   Response: 16%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              %↓CGI-S from BL\                                                                                                                                                                                                                       10.7% (↓CGI-S)\                                                                                                                                                                                                                                                                                                                                                          9.8% (↓CGI-S)\                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              %↑ CGAS from BL\                                                                                                                                                                                                                       18,8% (↑CGAS)                                                                                                                                                                                                                                                                                                                                                            12.8% (↑ CGAS)                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: CY-BOCS ↓≥30% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Mataix-Cols *et al*. \[[@r114]\]                           2014       King's College London, Institute of Psychiatry, London, UK                                                                                                                                                                                                                  27 children and adolescents with OCD (CY-BOCS≥16); 13 to D-cycloSer, 14 to placebo                                                                                                                                                          DB RCT of Exposure and response prevention therapy (ERP) + D-cycloSer 50 mg after each session *vs*. ERP + placebo × 17 wk                                                                                                                                                                                                                    Effect: % ↓CY-BOCS score from BL.\                                                                                                                                                                                                     59.3% (↓CY-BOCS)                                          Response: 64.2% (CY-BOCS ↓≥35% from BL); Remission: 42.8% (CY-BOCS ≤10)              Exposure and response prevention therapy (ERP) + D-cycloSer 50 mg after each session                                                                                                                                      60% (↓CY-BOCS)                                                      Response: 61.5% (CY-BOCS ↓≥35% from BL); Remission: 53.8% (CY-BOCS score ≤10)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: CY-BOCS ↓≥35% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: CY-BOCS score ≤ 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Afshar *et al*. \[[@r115]\]                                2014       Isfahan Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran                                                                                                                                                                                31 Y-BOCS≥16 to\                                                                                                                                                                                                                            12-wk, double-blind, placebo-controlled                                                                                                                                                                                                                                                                                                       Treatment effects: ↓Y-BOCS score from BL; response (r): Y-BOCS ↓≥25% from BL after 12 weeks                                                                                                                                            8.33% (↓Y-BOCS) after 12 weeks                            14.28% (Y-BOCS ↓≥25% from BL after 12 weeks)                                         Topiramate (range 100-200, mean dose: 137.5 mg/day), initial dose of 25 mg/day increased by 25 mg weekly to a maximum 200 mg/day                                                                                          19.81% (↓Y-BOCS) after 12 weeks                                     53.84% (Y-BOCS ↓≥25% from BL to 12 weeks)
                                                                                                                                                                                                                                                                                                                                                    -*N*=16 Topiramate (mean dose: 137.5 mg/day)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                    -*N*=15 Placebo\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                    Add-on on current SSRIs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Sarris *et al*. \[[@r116]\]                                2015       Department of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, VIC, Australia                                                                                                                                                                      34 to:\                                                                                                                                                                                                                                     16-wk, double-blind, placebo-controlled, randomised trial                                                                                                                                                                                                                                                                                     Treatment effects: ↓Y-BOCS score from BL; response: Y-BOCS ↓≥35% after 16 weeks                                                                                                                                                        19.5% (↓Y-BOCS);                                          27% (Y-BOCS ↓≥35% from BL)                                                           *N*AC (1.5 g q 12 h)                                                                                                                                                                                                      21% (↓Y-BOCS)                                                       20% (Y-BOCS ↓≥35% from BL)
                                                                                                                                                                                                                                                                                                                                                    *N*=18 3g/day *N*AC or *N*=16 Placebo\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                    (Y-BOCS≥16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Pittenger *et al*. \[[@r117]\]                             2015       Departments of Psychiatry and Psychology, Yale Child Study Center, Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT, USA                                                                                                           40 DR OCD patients (SSRI/Clomi non-responders): 20 to riluzole, 18 to placebo                                                                                                                                                               DB RCT of add-on riluzole (50 mg/day) *vs*. placebo × 12 wk                                                                                                                                                                                                                                                                                   Effect: % ↓Y-BOCS score from BL; Partial response: Y-BOCS ↓≥25% from BL; Response: Y-BOCS ↓≥35% from BL                                                                                                                                11% (↓Y-BOCS)                                             Partial or complete response: 11%                                                    Add-on riluzole 50 mg/day after 2-week placebo lead-in phase                                                                                                                                                              15% (↓Y-BOCS)                                                       Partial or complete\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  response: 26,3%

  Jahanbakhsh *et al*. \[[@r118]\]                           2016       Pharmaceutical Research Center, Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran                                                                                                                                  30 OCD patients currently treated with SSRI; 15 to *W. somnifera*, 15 to placebo                                                                                                                                                            DB RCT of add-on *W. somnifera* extract 120 mg/day *vs*. placebo × 6 wk                                                                                                                                                                                                                                                                       Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       11.1% (↓Y-BOCS)                                                                                                                                W. somnifera extract 120 mg/day                                                                                                                                                                                           46.2% (↓Y-BOCS)                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              no criterion for response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Paydary *et al*. \[[@r119]\]                               2016       Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran                                                                                                                                                              44 drug naïve OCD patients (Y-BOCS ≥21); 22 to *N*AC add-on, 22 to placebo add-on                                                                                                                                                           Multicentre DB RCT of fluvoxamine 200 mg/day + *N*AC 2000 mg/day *vs*. fluvoxamine 200 mg/day + placebo × 10 wk                                                                                                                                                                                                                               Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       30.3 (↓Y-BOCS)                                            Response: 22.7%                                                                      Fluvoxamine 100 mg/day for × first 4 weeks → 200 mg/day; + *N*AC 1000 mg/day × 1^st^ week → 2000 mg/day                                                                                                                   39% (↓Y-BOCS)                                                       Response: 54.5%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: Y-BOCS ≤ 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Khalkhali *et al*. \[[@r120]\]                             2016       Department of Psychiatry, Guilan University of Medical Sciences, Rasht, Iran                                                                                                                                                                                                53 DR to:\                                                                                                                                                                                                                                  12-wk, double blind, placebo-controlled RCT of 100 mg/day add-on lamotrigine to SSRIs in DR OCD-patients                                                                                                                                                                                                                                      Treatment effects:\                                                                                                                                                                                                                    17.7% (↓Y-BOCS);                                                                                                                               Adjunctive lamotrigine -doses (fixed 100 mg/day) (25→100 mg/day during the first 4 weeks, increments of 25 mg/week)                                                                                                       32.5% (↓Y-BOCS);                                                    
                                                                                                                                                                                                                                                                                                                                                    -N=26 Lamotrigine\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ↓Y-BOCS score from BL; response: Y-BOCS ↓\>25% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                    -N=27 placebo\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (at week 12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                    Y-BOCS≥21 with stable SRIs dosages × at least 3 months before the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Rutrick *et al*. \[[@r121]\]                               2016       Adams Clinical Trials, Watertown, MA, USA                                                                                                                                                                                                                                   50 DR to\                                                                                                                                                                                                                                   Multicentre, randomised, DB, add-on phase 2 study × 16 wk                                                                                                                                                                                                                                                                                     Treatment effects: ↓Y-BOCS from BL; Response (Y-BOCS ↓≥25% from BL) at week 17                                                                                                                                                         32.06% (↓Y-BOCS)                                          50% (Y-BOCS ↓≥25% from BL)                                                           (4 week up-titration period → 12-weeks fixed-dose\                                                                                                                                                                        26.59% (↓Y-BOCS)                                                    34.5% (Y-BOCS ↓≥25% from BL)
                                                                                                                                                                                                                                                                                                                                                    N=24 placebo or\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                200 mg Mavoglurant\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                    7N=26 Mavoglurant (augmentation to SSRIs) (Y-BOCS≥16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           q 12 h →\                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    3-weeks tapering-off                                                                                                                                                                                                                                                                          

  Feng *et al*. \[[@r122]\]                                  2016       Department of Psychiatry, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China                                                                                                                                                                                   360 OCD patients with Y-BOCS ≥ 16 randomised to GROUP A (*N*=120) GROUP B (*N*=120) or GROUP C (*N*=120)                                                                                                                                    SB RCT of TEAS with CBT + clomi (GROUP A) *vs*. TEAS with CBT + placebo (GROUP B) *vs*. sham TEAS with CBT + clomi (GROUP C) × 12 wk                                                                                                                                                                                                          Effect: % ↓Y-BOCS score from BL, Response: Y-BOCS ↓≥35% from BL, Remission: CY-BOCS score ≤ 12                                                                                                                                         GROUP B: 45% (↓Y-BOCS)\                                   GROUP B: Response: 82.5% Remission: 22.5% GROUP C: Response: 67.5% Remission: 9.2%   GROUP A: Transcutaneous electrical acupoint stimulation combined with CBT + clomi                                                                                                                                         GROUP A: 59.3% (↓Y-BOCS)                                            GROUP A: Response: 89.2%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     GROUP C: 38.2% (↓Y-BOCS)                                                                                                                                                                                                                                                                                                                                                                                                                     Remission: 29.2%

  de Leeuw *et al*. \[[@r123]\]                              2017       Altrecht Academic Anxiety Center, Utrecht, The Netherlands                                                                                                                                                                                                                  39 patients with OCD randomised to D-cycloSer (*N*=19) or placebo (*N*=20) in add-on                                                                                                                                                        DB RCT of Exposure and response prevention therapy (ERP) + D-cycloSer 125 mg/day *vs*. ERP + placebo × 8 wk                                                                                                                                                                                                                                   Effect: % ↓Y-BOCS score from BL.\                                                                                                                                                                                                      17% (↓Y-BOCS)                                             Partial or complete response: 35%                                                    Exposure and response prevention therapy (ERP) + D-cycloSer 125 mg/day                                                                                                                                                    25.2% (↓Y-BOCS)                                                     Partial or complete response: 90%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Y-BOCS\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ↓≥30% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Asnaani *et al*. \[[@r124]\]                               2017       Department of Psychiatry, Center for the Treatment and Study of Anxiety, University of Pennsylvania, Philadelphia, PA, USA                                                                                                                                                  100 patients on SRI with Y-BOCS ≥ 16 randomised to risperidone (*N*=40), EX/PR (*N*=40) or placebo (*N*=20)                                                                                                                                 RCT comparing EX/RP therapy + SSRI, risperidone (0.25 mg/day × 3 days, 0.5 mg/day × 4 days, → ↑0.5 mg/wk to max4.0 mg/day +SSRI *vs*. pill placebo + SSRI × 8 wk                                                                                                                                                                              Effect: ↑ QLESQ-SF score from BL; ↓SAS-SR and ↓SDS score from BL. No response criteria                                                                                                                                                 11.6% (↑ QLESQ-SF); 5.5% (↓ SAS-SR); 19% (↓ SDS)                                                                                               SSRI augmentation with either EX/RP therapy (17 twice-weekly, 90-min sessions) or risperidone (0.25 mg/d × 3 days, 0.5 mg/d × 4 days, → ↑0.5 mg/week to max 4.0 mg/day)                                                   EX/RP therapy: 20.6%\                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (↑ QLESQ-SF); 14.8% (↓ SAS-SR); 51.5%\                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (↓ SDS)\                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Risperidone: 5.7%\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (↑ QLESQ-SF) 4.5%\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (↓ SAS-SR) 20.6%\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (↓ SDS)                                                             

  **Author(s)**                                              **Year**   **Affiliation/**\                                                                                                                                                                                                                                                           **Population (N)**                                                                                                                                                                                                                          **Design**                                                                                                                                                                                                                                                                                                                                    **Outcome Measures (Response Criteria)**                                                                                                                                                                                               **Placebo Effect (%)**                                    **Placebo Responders (%)**                                                           **Drug(s) or other Treatment than Placebo**                                                                                                                                                                               **Drug Effect (%)**                                                 **Drug Responders (%)**
                                                                        **Country**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Ahmadpanah *et al*.\[[@r125]\]                             2017       Hamadan University of Medical Sciences (HUMS), Behavioral Disorders and Substance Abuse Research Center, Hamadan, Iran                                                                                                                                                      43 DR OCD patients (not responding to SSRI or Clomi) to buprenorphine (*N*=23) or placebo (*N*=20)                                                                                                                                          DB RCT of DR patients with stabilised SSRI or clomi to add-on buprenorphine or placebo × 12 wk                                                                                                                                                                                                                                                Effect: % ↓Y-BOCS score from BL.\                                                                                                                                                                                                      7% (↓Y-BOCS)                                              Partial or complete response: 25%                                                    Buprenorphine tablets (2-4 g; sublingual) daily                                                                                                                                                                           17,5% (↓Y-BOCS)                                                     Partial or complete response: 39%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Modarresi *et al*. \[[@r126]\]                             2017       Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran                                                                                                                                                                              32 DR OCD patients (failing at least 3 adequate trials of antidepressant, including clomi) and Y-BOCS ≥ 24 randomised to memantine (*N*=16) or placebo (*N*=16)                                                                             DB RCT of add-on memantine 20 mg/day *vs*. placebo × 12 wk                                                                                                                                                                                                                                                                                    Effect: % ↓Y-BOCS score from BL; Response: Y-BOCS ↓≥35% from BL                                                                                                                                                                        -0.2% (↓Y-BOCS)                                           Response: 0%                                                                         Add-on memantine 20 mg/day                                                                                                                                                                                                31% (↓Y-BOCS)                                                       Response: 73.3%

  Costa *et al*. \[[@r127]\]                                 2017       Department & Institute of Psychiatry, University of São Paulo Medical School, São Paulo-SP, Brazil                                                                                                                                                                          40 DR OCD patients (not responding to SSRI or clomi) randomised to *N*AC (*N*=18) or placebo (*N*=22)                                                                                                                                       DB RCT of add-on *N*AC (up to 3000 mg/day) *vs*. placebo × 16 wk                                                                                                                                                                                                                                                                              Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       12.1% (↓Y-BOCS)                                           Response: 26.3%                                                                      Add-on *N*AC, 1,200 mg/day for the first week, 2,400 mg in the second week, 3,000 mg/day from the third week on                                                                                                           16.8% (↓Y-BOCS)                                                     Response: 37.5%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥25% from BL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Arabzadeh *et al*. \[[@r128]\]                             2017       Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran                                                                                                                                                                          44 drug naïve OCD patients (Y-BOCS ≥21) randomised to L-carnosine (*N*=22) or placebo (*N*=22)                                                                                                                                              DB RCT of fluvoxamine 100 - 200 mg/day + L‐carnosine 1000 mg/day *vs*. fluvoxamine 100 - 200 mg/day + placebo × 10 wk                                                                                                                                                                                                                         Effect: % ↓Y-BOCS score from BL\                                                                                                                                                                                                       24.3 (↓Y-BOCS)                                            Partial: 45.5%; Complete: 9.1%; Remission: 9.1%                                      Fluvoxamine 100 mg/day × 4 wk→200 mg/day × 6 wk + L‐carnosine 1000 mg/day                                                                                                                                                 35.3 (↓Y-BOCS)                                                      Partial: 45.5%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Partial response: Y-BOCS ↓≥25% from BL;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Complete: 36.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Response: Y-BOCS ↓≥35% from BL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Remission: 27.3%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Remission: Y-BOCS ≤ 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations used:** BDI=Beck Depression Inventory; BDZs=benzodiazepines; BL=baseline; BT= Behaviour Therapy; CBT=Cognitive-Behavioural Therapy; CGI=Clinical Global Impressions scale-i=improvement, s=severity; clomi=clomipramine; clonz=clonazepam; CCMD-2=Chinese Criteria of Mental Disorders, 2nd edition; CPRS=Comprehensive Psychopathological Rating Scale, Karolinska institutet; DB=double-blind; DLPFC=dorsolateral prefrontal cortex; DR=drug-resistant/treatment-resistant; D-cycloSer=D-cycloserine; EPA=eicosapentaenoic acid; ERP=exposure and ritual (response) prevention; GAF=Global Assessment of Functioning; GVC=gamma ventral capsulotomy; halo=haloperidol; Ham-D=Hamilton Depression Rating Scale; MOCI=Maudsley Obsessional Compulsive Inventory; MT=motor threshold; *N*AC=*N*-Acetylcysteine; NIMH= National Institute of Mental Health Global Obsessive-Compulsive Scale; OCS= Obsessive Compulsive Scale; PGI=Patient's Global Impressions; RegSert=Standard sertraline dose; SloSert=slowly titrated sertraline; SROC=Self-Rating Obsessive-Compulsive Personality Inventory; SRON=Self-Rating Obsessional Neurotic Scale; wk=weeks; Y-BOCS=Yale-Brown Obsessive-Compulsive Scale; YGTSS, Yale Global Tick Severity Scale; ZnSO~4~=zinc sulfate; ↑=increase; ↓=reduction; \*Patients were not DSM-IV OCD at inclusion, because they had responded to previous trial; hence, actual baseline was factitious and the differences observed were modest for all groups, meaning that treatment continued to work.

[^1]: Additional members of the Sapienza Group for the Study of the Placebo Effect in Psychiatric Disorders:

[^2]: Gaia Ruberto, M.D., Ph.D.; Elisa Ambrosi, M.D.; Alexia E. Koukopoulos, M.D., Ph.D.; Giovanni Manfredi, M.D., Ph.D.; Giorgio Monaco, M.D.; Isabella Panaccione, M.D., Ph.D.; Silvia Gubbini, M.D.; Pietro De Rossi, M.D., Ph.D.; Daria Piacentino, M.D., Ph.D.; Claudio Verzura, M.D.; Aldea Bandiera, Psy.D.; Manuela Trevisi, M.D.; Giada Trovini, M.D.; Livia Sanna, M.D.; Salvatore Rizzato, M.D.; Daniela Pucci, M.D.; Ilaria Falcone, M.D.; Francesco Pompei, M.D., Ph.D.; Nicoletta Girardi, M.D.; Alessio Simonetti, M.D.; Floriana Pazzelli, M.D.; Stefania Zangaro, M.D.; Martina Curto, M.D.; Gemma Callovini, M.D.; Simone Pallottino, M.D.; Giulia Serra, M.D.; Giulia Armani, Psy.D.; Teodolinda Zoppi, M.D.; Serena Sorice, M.D.; Federica Caccia, M.D.; Alessio Padovano, M.D.; Giulia Giuseppin, M.D.; Matteo Caloro, M.D.; Federica Catalfio, Psy.D.; Giuseppa Calabrò, M.D.; Emanuela Danese, M.D.; Lorenzo Mazzarini, M.D., Ph.D.; Margherita Genisio, Psy.D.; C. Ludovica Telesforo, M.D.; Eleonora de Pisa, M.D.; Alessandro Emiliano Vento, M.D., Ph.D.; Franco Montebovi, M.D.; Paola Venturini, M.D.; Stefano Naim, M.D.; Luca Bonanni, M.D.; Maria Elena Seretti, M.D.; Andrea Buscajoni, M.D.; Matteo Maggiora, M.D.; Gloria Giordano, M.D.; Jessica Trinetti, M.D.; Chiara Chetoni, M.D.; Edoardo Spinazzola, M.D.; Gloria Angeletti, M.D.; Arianna Zamparelli, M.D.; Giorgia Dimitri, M.D.; Federica Caccia, M.D.; Alessandra Talamo, M.D., Ph.D.; Delfina Janiri, M.D.; Carlotta Teodori, Psy.D.; Giulio M. Porfiri, M.D.
